Prestige Consumer Healthcare (PBH) 10-Q 6 Nov 14 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Prestige Brands Holdings, Inc.	'
Entity Central Index Key	'0001295947	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	52,172,727

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	'	'	'	'
Net sales	$180,005	$165,507	$324,546	$307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Operating Expenses	'	'	'	'
Advertising and promotion	25,044	24,547	44,140	43,228
General and administrative	27,128	11,619	44,134	23,253
Depreciation and amortization	3,852	3,294	6,813	6,562
Total operating expenses	56,024	39,460	95,087	73,043
Operating income	46,518	53,762	89,321	103,203
Other (income) expense	'	'	'	'
Interest income	-15	-25	-47	-28
Interest expense	18,208	16,464	32,893	32,372
Total other (income) expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Earnings per share:	'	'	'	'
Basic (in USD per share)	$0.32	$0.64	$0.64	$1.04
Diluted (in USD per share)	$0.31	$0.63	$0.63	$1.03
Weighted average shares outstanding:	'	'	'	'
Basic (in shares)	52,088	51,463	52,023	51,343
Diluted (in shares)	52,594	52,219	52,564	52,130
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	$5,633	$33,914	$25,091	$54,607

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$21,748	$28,331
Accounts receivable, net	98,644	65,050
Inventories	82,875	65,586
Deferred income tax assets	9,171	6,544
Prepaid expenses and other current assets	9,935	11,674
Total current assets	222,373	177,185
Property and equipment, net	12,420	9,597
Goodwill	293,993	190,911
Intangible assets, net	2,163,947	1,394,817
Other long-term assets	32,937	23,153
Total Assets	2,725,670	1,795,663
Current liabilities	'	'
Current portion of long term debt	7,200	0
Accounts payable	58,538	48,286
Accrued interest payable	12,086	9,626
Other accrued liabilities	34,086	26,446
Total current liabilities	111,910	84,358
Long-term debt	'	'
Principal amount	1,691,400	937,500
Less unamortized discount	-6,289	-3,086
Long-term debt, net of unamortized discount	1,685,111	934,414
Deferred income tax liabilities	334,297	213,204
Other long-term liabilities	313	327
Total Liabilities	2,131,631	1,232,303
Commitments and Contingencies — Note 16	'	'
Stockholders' Equity	'	'
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 52,426 shares at September 30, 2014 and 52,021 shares at March 31, 2014	524	520
Additional paid-in capital	421,574	414,387
Treasury stock, at cost - 254 shares at September 30, 2014 and 206 shares at March 31, 2014	-3,034	-1,431
Accumulated other comprehensive (loss) income, net of tax	-7,365	739
Retained earnings	182,340	149,145
Total Stockholders' Equity	594,039	563,360
Total Liabilities and Stockholders' Equity	$2,725,670	$1,795,663

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Stockholders' Equity:	'	'
Preferred stock, par value (in USD per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	52,426,000	52,021,000
Treasury stock, shares	254,000	206,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating Activities	'	'
Net income	$33,195	$53,484
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	6,815	6,562
Deferred income taxes	11,496	4,355
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs	3,403	2,487
Amortization of debt discount	687	798
Loss (Gain) on sale or disposal of property and equipment	56	-3
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-8,363	-5,712
Inventories	7,264	821
Prepaid expenses and other current assets	3,114	2,619
Accounts payable	-5,647	-1,125
Accrued liabilities	2,640	-10,663
Net cash provided by operating activities	57,058	55,598
Investing Activities	'	'
Purchases of property and equipment	-1,380	-2,319
Proceeds from the sale of property and equipment	0	3
Proceeds from sale of business	18,500	0
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666	0
Acquisition of the Hydralyte brand	-77,991	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	-55,215
Net cash provided by (used in) investing activities	-810,537	-57,531
Financing Activities	'	'
Term loan borrowings	720,000	0
Term loan repayments	-25,000	-7,500
Repayments under revolving credit agreement	-58,500	-35,500
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	-16,072	-275
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	-1,660	-278
Net cash provided by (used in) financing activities	747,212	12,940
Effects of exchange rate changes on cash and cash equivalents	-316	156
(Decrease) Increase in cash and cash equivalents	-6,583	11,163
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,748	26,833
Interest paid	27,349	29,516
Income taxes paid	$4,716	$8,468

Business_and_Basis_of_Presenta

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Business and Basis of Presentation	'
	Business and Basis of Presentation
	Nature of Business
	Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets.  Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.
	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
	Revision
	We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2014 are uninsured.
	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.
	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.
	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $9.4 million and $17.1 million for the three and six months ended September 30, 2014, respectively, and $9.1 million and $15.7 million for the three and six months ended September 30, 2013, respectively.
	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
	Recently Issued Accounting Standards
	In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

Acquisitions	6 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	Acquisition of Insight Pharmaceuticals
	On September 3, 2014, the Company completed its previously announced acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extends the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also adds brands to the Company's cough/cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing.
	The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.
	(In thousands)	3-Sep-14
	Cash acquired	$	3,507
	Accounts receivable	25,784
	Inventories	23,559
	Deferred income tax assets - current	860
	Prepaids and other current assets	1,407
	Property, plant and equipment	2,308
	Goodwill	103,255
	Intangible Assets	724,374
	Total assets acquired	885,054
	Accounts payable	16,079
	Accrued expenses	8,003
	Deferred income tax liabilities - long term	107,799
	Total liabilities assumed	131,881
	Total purchase price	$	753,173
	Based on this analysis, we allocated $599.6 million to non-amortizable intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 16.1 years.
	We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.
	The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the three and six months ended September 30, 2014 were $12.7 million. Net loss for the three and six months ended September 30, 2014 was $2.0 million. On September 3, 2014 we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.
	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.
	(In thousands, except per share data)		Six Months Ended September 30, 2014
	Revenues		$	393,140
	Net income		$	37,957
	Earnings per share:
	Basic		$	0.73
	Diluted		$	0.72
	(In thousands, except per share data)		Six Months Ended September 30, 2013
	Revenues		$	389,490
	Net income		$	53,511
	Earnings per share:
	Basic		$	1.04
	Diluted		$	1.03
	Acquisition of the Hydralyte brand
	On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on the balance sheet and our existing senior secured credit facility.
	Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.
	The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.
	(In thousands)	30-Apr-14
	Inventories	$	1,970
	Property, plant and equipment, net	1,267
	Goodwill	1,224
	Intangible assets, net	73,580
	Total assets acquired	78,041
	Accrued expenses	38
	Other long term liabilities	12
	Total liabilities assumed	50
	Net assets acquired	$	77,991
	Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.
	We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.
	The pro-forma effect of this acquisition on revenues and earnings was not material.
	Acquisition of Care Pharmaceuticals Pty Ltd.
	On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.
	The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also includes a line of brands for children including, Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio and are included in our International OTC Healthcare segment.
	The Care Pharma acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	1-Jul-13
	Cash acquired	$	1,546
	Accounts receivable	1,658
	Inventories	2,465
Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761
Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 13.1 years.
We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.
The pro-forma effect of this acquisition on revenues and earnings was not material.

Accounts_Receivable

Accounts Receivable	6 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable consist of the following:
	(In thousands)	September 30,			March 31,
		2014			2014
	Components of Accounts Receivable
	Trade accounts receivable	$	107,943		$	73,632
	Other receivables	2,176			1,360
		110,119			74,992
	Less allowances for discounts, returns and uncollectible accounts	(11,475		)	(9,942		)
	Accounts receivable, net	$	98,644		$	65,050

Inventories

Inventories	6 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following:
	(In thousands)	September 30,		March 31,
		2014		2014
	Components of Inventories
	Packaging and raw materials	$	3,929	$	3,099
	Work in process	3,456		—
	Finished goods	75,490		62,487
	Inventories	$	82,875	$	65,586
	Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $4.8 million and $1.1 million at September 30, 2014 and March 31, 2014, respectively, related to obsolete and slow-moving inventory. Following the acquisition of the Hydralyte brand on April 30, 2014, we manufacture certain Hydralyte products in Australia.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following:
	(In thousands)	September 30,			March 31,
		2014			2014
	Components of Property and Equipment
	Machinery	$	4,245		$	1,927
	Computer equipment and software	10,183			8,923
	Furniture and fixtures	2,703			1,858
	Leasehold improvements	4,823			4,734
		21,954			17,442
	Accumulated depreciation	(9,534		)	(7,845		)
	Property and equipment, net	$	12,420		$	9,597
	We recorded depreciation expense of $0.9 million and $0.5 million for the three months ended September 30, 2014 and September 30, 2013, respectively, and $1.6 million and $1.1 million for the six months ended September 30, 2014 and September 30, 2013, respectively.

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2014
Goodwill [Abstract]	'
Goodwill	'
	Goodwill
	As described in Note 18 to these Consolidated Financial Statements, we have realigned our reportable segments with how we currently operate, review and evaluate the results of our business. A reconciliation of the activity affecting goodwill by reportable segment is as follows:
	(In thousands)	North American OTC		International OTC			Household		Consolidated
		Healthcare		Healthcare			Cleaning
	Balance — March 31, 2014	$	160,157	$	23,365		$	7,389	$	190,911
	Additions	103,254		1,224			—		104,478
	Effects of foreign currency exchange rates	—		(1,396		)	—		(1,396		)
	Balance — September 30, 2014	$	263,411	$	23,193		$	7,389	$	293,993
	As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.3 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.
	Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.
	On an annual basis, during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.
	At March 31, 2014, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2014. As of September 30, 2014, there have been no triggering events that would indicate potential impairment of goodwill.
	The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value that is utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

Intangible_Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2014
Intangible Assets [Abstract]	'
Intangible Assets	'
	Intangible Assets
	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived			Totals
		Lived			Trademarks
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
	Additions	673,180			124,774			797,954
	Reductions	—			(17,674		)	(17,674		)
	Effects of foreign currency exchange rates	(6,000		)	(95		)	(6,095		)
	Balance — September 30, 2014	1,941,058			311,745			2,252,803
	Accumulated Amortization
	Balance — March 31, 2014	—			83,801			83,801
	Additions	—			5,064			5,064
	Effects of foreign currency exchange rates	—			(9		)	(9		)
	Balance — September 30, 2014	—			88,856			88,856
	Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
	Intangible Assets, net by Reportable Segment:
	North American OTC Healthcare	$	1,723,498		$	196,145		$	1,919,643
	International OTC Healthcare	97,740			1,449			99,189
	Household Cleaning	119,820			25,295			145,115
	Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
	As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we allocated $17.7 million to the intangible assets.
	Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount.  Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.
	On an annual basis during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.
	In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the fourth quarter of fiscal 2014.  We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of September 30, 2014 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the six months ended September 30, 2014.
	The weighted average remaining life for finite-lived intangible assets at September 30, 2014 was approximately 14.5 years and the amortization expense for the three and six months ended September 30, 2014 was $2.8 million and $5.1 million, respectively. At September 30, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2015 (Remaining six months ending March 31, 2015)		$	7,740
	2016		15,554
	2017		15,554
	2018		15,554
	2019		15,554
	Thereafter		152,933
			$	222,889

Other_Accrued_Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
	(In thousands)	September 30,		March 31,
		2014		2014
	Accrued marketing costs	$	16,187	$	11,812
	Accrued compensation costs	5,129		6,232
	Accrued broker commissions	851		1,019
	Income taxes payable	1,186		1,854
	Accrued professional fees	2,344		2,002
	Deferred rent	1,109		1,258
	Accrued production costs	3,364		1,506
	Other accrued liabilities	3,916		763
		$	34,086	$	26,446

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	2012 Senior Notes:
	On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.
	2012 Term Loan and 2012 ABL Revolver:
	On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.
	On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loan"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date.  In addition, Term Loan Amendment No.1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.
	On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loan") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including but not limited to additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). Under the Term Loan Amendment No.2, we are required to make quarterly payments each equal to 0.25% of the original principal amount of the Term B-2 Loan, with the balance expected to be due on the seventh anniversary of the closing date. Therefore, we have presented $7.2 million of current portion of long term debt as of September 30, 2014.
	The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the six months ended September 30, 2014, the average interest rate on the 2012 Term Loan was 4.9%.
	Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.
	On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.7%.
	2013 Senior Notes:
	On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.
	Redemptions and Restrictions:
	At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
	At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
	The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At September 30, 2014, we were in compliance with the covenants under our long-term indebtedness.
	At September 30, 2014, we had an aggregate of $32.9 million of unamortized debt issuance costs and $6.3 million of unamortized debt discount, the total of which is comprised of $9.4 million related to the 2012 Senior Notes, $6.6 million related to the 2013 Senior Notes, $21.8 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.
	During the six months ended September 30, 2014, we borrowed a net amount of $66.1 million against the 2012 ABL Revolver.
	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	September 30,			March 31,
		2014			2014
	2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
	2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
	2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	262,500			287,500
	2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	720,000			—
	2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
		1,698,600			937,500
	Current portion of long-term debt	7,200			—
		1,691,400			937,500
	Less: unamortized discount	(6,289		)	(3,086		)
	Long-term debt, net of unamortized discount	$	1,685,111		$	934,414
	As of September 30, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2015 (remaining six months ending March 31, 2015)	$	3,600
	2016	7,200
	2017	73,300
	2018	7,200
	2019	269,700
	Thereafter	1,337,600
		$	1,698,600

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.
	The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:
	Level 1 - Quoted market prices for identical instruments in active markets;
	Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and
	Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.
	The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-1 Loan, Term B-2 Loan, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At September 30, 2014 and March 31, 2014, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.
	At September 30, 2014 and March 31, 2014, the carrying value of our 2013 Senior Notes was $400.0 million. The fair value of our 2013 Senior Notes was $377.0 million and $408.5 million at September 30, 2014 and March 31, 2014, respectively.
	At September 30, 2014 and March 31, 2014, the carrying value of our 2012 Senior Notes was $250.0 million. The fair value of our 2012 Senior Notes was $266.9 million and $280.6 million at September 30, 2014 and March 31, 2014, respectively.
	At September 30, 2014 and March 31, 2014, the carrying value of the Term B-1 Loan was $262.5 million. The fair value of the Term B-1 Loan was $261.2 million and $288.9 million at September 30, 2014 and March 31, 2014, respectively.
	At September 30, 2014 the carrying value of the Term B-2 Loan was $720.0 million. The fair value of the Term B-2 Loan was $718.2 million at September 30, 2014. Because the Term B-2 Loan was entered into on September 3, 2014, there were no outstanding loan balances as of March 31, 2014.
	At September 30, 2014, the carrying value and fair value of the 2012 ABL Revolver was $66.1 million. There were no outstanding borrowings under the 2012 ABL Revolver at March 31, 2014.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.
	Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on the Company's common stock through September 30, 2014.
	During the three and six months ended September 30, 2014, we repurchased 13,924 shares and 47,664 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and six months ended September 30, 2013, we repurchased zero shares and 10,726 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2014 and 2013 were at an average price of $33.63 and $25.96, respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss) Income	6 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive (Loss) Income	'
	Accumulated Other Comprehensive (Loss) Income
	The table below presents accumulated other comprehensive (loss) income (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.
	AOCI consisted of the following at September 30, 2014 and March 31, 2014:
		September 30,			March 31,
	(In thousands)	2014			2014
	Components of Accumulated Other Comprehensive (Loss) Income
	Cumulative translation adjustment	$	(7,365	)	$	739
	Total accumulated other comprehensive (loss) income, net of tax	$	(7,365	)	$	739

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended September 30,				Six Months Ended September 30,
	(In thousands, except per share data)	2014		2013		2014		2013
	Numerator
	Net income	$	16,463	$	32,792	$	33,195	$	53,484
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	52,088		51,463		52,023		51,343
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	506		756		541		787
	Denominator for diluted earnings per share	52,594		52,219		52,564		52,130
	Earnings per Common Share:
	Basic net earnings per share	$	0.32	$	0.64	$	0.64	$	1.04
	Diluted net earnings per share	$	0.31	$	0.63	$	0.63	$	1.03
	For the three months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation
	In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. On June 19, 2014, the Board of Directors amended the Plan to provide for the grant of an additional 1.8 million shares of the Company's stock, $0.01 par value, pursuant to the Plan, which amendment the Company's stockholders approved on August 5, 2014.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.
	During the three and six months ended September 30, 2014, pre-tax share-based compensation costs charged against income were $1.5 million and $3.4 million, respectively, and the related income tax benefit recognized was $0.5 million and $1.2 million, respectively. During the three and six months ended September 30, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $2.5 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.7 million, respectively.
	Restricted Shares
	Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan.  The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant, unless specified differently on the date of grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.
	On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 75,638 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 restricted stock units vest 33.3% per year over three years.
	The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the six months ended September 30, 2014 and 2013 was $33.30 and $30.19, respectively.
	A summary of the Company's restricted shares granted under the Plan is presented below:
					Weighted-
		Shares			Average
		(in thousands)			Grant-Date
	Restricted Shares				Fair Value
	Six months ended September 30, 2013
	Vested and nonvested at March 31, 2013	421.3			$	11.01
	Granted	120.6			30.19
	Vested and issued	(54.7	)		8.11
	Forfeited	(3.6	)		13.24
	Vested and nonvested at September 30, 2013	483.6			16.11
	Vested at September 30, 2013	83.1			9.63
	Six months ended September 30, 2014:
	Vested and nonvested at March 31, 2014	437.5			$	16.76
	Granted	104.4			33.3
	Vested and issued	(120.7	)		13.34
	Forfeited	(14.4	)		20.78
	Vested and nonvested at September 30, 2014	406.8			21.88
	Vested at September 30, 2014	76.6			11.62
	Options
	The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years.  The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.  On May 12, 2014, the Compensation Committee of our Board of Directors granted stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.
	The weighted-average grant-date fair value of the options granted during the six months ended September 30, 2014 and 2013 was $15.93 and $13.94, respectively.
		Six Months Ended September 30,
		2014				2013
	Expected volatility	47.3		%		48		%
	Expected dividends	$	—			$	—
	Expected term in years	6				6
	Risk-free rate	2.2		%		1.3		%
	A summary of option activity under the Plan is as follows:
					Weighted-				Weighted-	Aggregate
					Average				Average	Intrinsic
		Shares			Exercise				Remaining	Value
		(in thousands)			Price				Contractual	(in thousands)
	Options								Term
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013	1,386.40			$	10.43
	Granted	227.7			29.94
	Exercised	(539.4	)		9.54
	Forfeited or expired	(8.0	)		13.24
	Outstanding at September 30, 2013	1,066.70			15.02				6.5	$	16,110
	Exercisable at September 30, 2013	225.5			11.42				7.7	4,216
	Six months ended September 30, 2014:
	Outstanding at March 31, 2014	994.9			$	15.24
	Granted	307.5			33.5
	Exercised	(284.4	)		9.7
	Forfeited or expired	(32.5	)		25.61
	Outstanding at September 30, 2014	985.5			22.19				8	$	10,364
	Exercisable at September 30, 2014	416			14.31				6.8	7,514
	The aggregate intrinsic value of options exercised in the six months ended September 30, 2014 was $7.1 million.
	At September 30, 2014, there were $7.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 1.0 year.  The total fair value of options and restricted shares vested during the six months ended September 30, 2014 and 2013 was $4.2 million and $3.2 million, respectively.  For the six months ended September 30, 2014 and 2013, cash received from the exercise of stock options was $2.8 million and $5.1 million, respectively, and we realized $1.8 million and $1.7 million, respectively, in tax benefits from the tax deductions resulting from these option exercises. At September 30, 2014, there were 1.2 million shares available for issuance under the Plan.

Income_Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur.  The effective tax rates used in the calculation of income taxes were 41.9% and 12.1% for the three months ended September 30, 2014 and September 30, 2013, respectively. The effective tax rates used in the calculation of income taxes were 41.2% and 24.5%, for the six months ended September 30, 2014 and September 30, 2013, respectively. The increase in the effective tax rate for the three and six months ended September 30, 2014 was primarily due to the impact of certain non-deductible items related to acquisitions and state tax adjustments and a one-time benefit of $9.1 million to adjust our current and deferred tax balances as of September 30, 2013 for lower state income taxes. This benefit was primarily related to a law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.
	At September 30, 2014, wholly-owned subsidiaries of the Company had net operating loss carryforwards of approximately $78.2 million, which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020.  The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire.
	We had no change in our uncertain tax liability during the six months ended September 30, 2014. Therefore, the balance in our uncertain tax liability was $1.2 million at September 30, 2014 and March 31, 2014. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense.  We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	We are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.
	Lease Commitments
	We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. We required additional office space as a result of the closing of the acquisition of Insight. Therefore, in the first quarter of fiscal 2015, we amended our existing New York office lease to include an additional 15,470 square feet beginning October 2014 and extended the expiration of the combined lease through September 2020. These amounts have been included in the table below.
	The following summarizes future minimum lease payments for our operating leases as of September 30, 2014:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2015 (Remaining six months ending March 31, 2015)	$	859	$	344	$	1,203
	2016	1,612		311		1,923
	2017	1,772		77		1,849
	2018	1,856		—		1,856
	2019	1,864		—		1,864
	Thereafter	2,465		—		2,465
		$	10,428	$	732	$	11,160
	Rent expense for each of the three months ended September 30, 2014 and 2013 was $0.3 million and $0.5 million, respectively, while rent expense for each of the six months ended September 30, 2014 and 2013 was $0.7 million and $0.8 million, respectively.
	Purchase Commitments
	Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products.  Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2015 (Remaining six months ending March 31, 2015)	$	549
	2016	1,074
	2017	1,044
	2018	1,013
	2019	982
	Thereafter	560
		$	5,222

Concentrations_of_Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentrations of Risk	'
	Concentrations of Risk
	Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products.  We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores.  During the three and six months ended September 30, 2014, approximately 40.6% and 41.2%, respectively, of our total revenues were derived from our five top selling brands.  During the three and six months ended September 30, 2013, approximately 41.8% and 43.0%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 17.0% and 18.0%, respectively, of our gross revenues for the three and six months ended September 30, 2014, and approximately 19.2% and 20.4%, respectively, of our gross revenues for the three and six months ended September 30, 2013. At September 30, 2014, approximately 21.5% of accounts receivable were owed by the same customer.
	We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost.  We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels.  As a result, any such disruption could have a material adverse effect on our business, sales and profitability.
	At September 30, 2014, we had relationships with 101 third-party manufacturers.  Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 77.4% of gross sales for the six months ended September 30, 2014. At September 30, 2013, we had relationships with 50 third-party manufacturers.  Of those, we had long-term contracts with 22 manufacturers that produced items that accounted for approximately 77.9% of gross sales for the six months ended September 30, 2013. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

Business_Segments

Business Segments	6 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	Business Segments
	Beginning April 1, 2014, we began managing and reporting certain of our businesses separately and have therefore realigned our reportable segments to align with how we manage and evaluate the results of our business. These reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. The results of our previously reported OTC Healthcare segment is now separated into two reporting segments, the North American OTC Healthcare segment and the International OTC Healthcare segment, largely to reflect our international expansion due to recent acquisitions. Prior year amounts were reclassified to conform to the current reportable segments discussed above. Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.
	The tables below summarize information about our reportable segments.
		Three Months Ended September 30, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	138,138		$	17,331	$	25,246	$	180,715
	Elimination of intersegment revenues	(710		)	—		—		(710		)
	Third-party segment revenues	137,428			17,331		25,246		180,005
	Other revenues	150			23		1,091		1,264
	Total segment revenues	137,578			17,354		26,337		181,269
	Cost of sales	52,185			6,595		19,947		78,727
	Gross profit	85,393			10,759		6,390		102,542
	Advertising and promotion	21,442			3,035		567		25,044
	Contribution margin	$	63,951		$	7,724	$	5,823	77,498
	Other operating expenses								30,980
	Operating income								46,518
	Other expense								18,193
	Income before income taxes								28,325
	Provision for income taxes								11,862
	Net income								$	16,463
		Six Months Ended September 30, 2014
	(In thousands)	North			International		Household		Consolidated
		American			OTC		Cleaning
		OTC			Healthcare
		Healthcare
	Gross segment revenues	$	249,112		$	31,022	$	45,839	$	325,973
	Elimination of intersegment revenues	(1,427		)	—		—		(1,427		)
	Third-party segment revenues	247,685			31,022		45,839		324,546
	Other revenues	327			58		2,040		2,425
	Total segment revenues	248,012			31,080		47,879		326,971
	Cost of sales	94,526			11,679		36,358		142,563
	Gross profit	153,486			19,401		11,521		184,408
	Advertising and promotion	37,794			5,375		971		44,140
	Contribution margin	$	115,692		$	14,026	$	10,550	140,268
	Other operating expenses								50,947
	Operating income								89,321
	Other expense								32,846
	Income before income taxes								56,475
	Provision for income taxes								23,280
	Net income								$	33,195
		Three Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	132,944		$	9,008	$	24,374	$	166,326
	Elimination of intersegment revenues	(819		)	—		—		(819		)
	Third-party segment revenues	132,125			9,008		24,374		165,507
	Other revenues	150			7		1,281		1,438
	Total segment revenues	132,275			9,015		25,655		166,945
	Cost of sales	50,987			4,338		18,398		73,723
	Gross profit	81,288			4,677		7,257		93,222
	Advertising and promotion	22,547			1,446		554		24,547
	Contribution margin	$	58,741		$	3,231	$	6,703	68,675
	Other operating expenses								14,913
	Operating income								53,762
	Other expense								16,439
	Income before income taxes								37,323
	Provision for income taxes								4,531
	Net income								$	32,792
		Six Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	251,880		$	12,422	$	43,666	$	307,968
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	251,061			12,422		43,666		307,149
Other revenues	300			14		1,994		2,308
Total segment revenues	251,361			12,436		45,660		309,457
Cost of sales	94,533			5,803		32,875		133,211
Gross profit	156,828			6,633		12,785		176,246
Advertising and promotion	40,097			1,710		1,421		43,228
Contribution margin	$	116,731		$	4,923	$	11,364	133,018
Other operating expenses								29,815
Operating income								103,203
Other expense								32,344
Income before income taxes								70,859
Provision for income taxes								17,375
Net income								$	53,484
The tables below summarize information about our segment revenues from similar product groups.
	Three Months Ended September 30, 2014
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	29,072		$	792	$	—	$	29,864
Cough & Cold	24,771			5,460		—		30,231
Women's Health	9,119			658		—		9,777
Gastrointestinal	20,896			5,598		—		26,494
Eye & Ear Care	21,405			4,028		—		25,433
Dermatologicals	17,459			687		—		18,146
Oral Care	12,934			127		—		13,061
Other OTC	1,922			4		—		1,926
Household Cleaning	—			—		26,337		26,337
Total segment revenues	$	137,578		$	17,354	$	26,337	$	181,269
	Six Months Ended September 30, 2014
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	54,103		$	1,457	$	—	$	55,560
Cough & Cold	44,814			10,259		—		55,073
Women's Health	9,487			1,176				10,663
Gastrointestinal	41,534			8,096		—		49,630
Eye & Ear Care	42,130			8,670		—		50,800
Dermatologicals	29,720			1,229		—		30,949
Oral Care	23,121			189		—		23,310
Other OTC	3,103			4		—		3,107
Household Cleaning	—			—		47,879		47,879
Total segment revenues	$	248,012		$	31,080	$	47,879	$	326,971
	Three Months Ended September 30, 2013
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	29,343		$	698	$	—	$	30,041
Cough & Cold	28,695			5,023		—		33,718
Women's Health	501			633		—		1,134
Gastrointestinal	21,695			301		—		21,996
Eye & Ear Care	19,378			1,625		—		21,003
Dermatologicals	17,716			605		—		18,321
Oral Care	13,028			130		—		13,158
Other OTC	1,919			—		—		1,919
Household Cleaning	—			—		25,655		25,655
Total segment revenues	$	132,275		$	9,015	$	25,655	$	166,945
	Six Months Ended September 30, 2013
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	57,479		$	727	$	—	$	58,206
Cough & Cold	49,193			6,006		—		55,199
Women's Health	988			633		—		1,621
Gastrointestinal	43,453			312		—		43,765
Eye & Ear Care	39,710			3,885		—		43,595
Dermatologicals	32,347			696		—		33,043
Oral Care	24,114			177		—		24,291
Other OTC	4,077			—		—		4,077
Household Cleaning	—			—		45,660		45,660
Total segment revenues	$	251,361		$	12,436	$	45,660	$	309,457
During the three months ended September 30, 2014 and September 30, 2013, approximately 82.7% and 86.9%, respectively of our total segment revenues were from customers in the United States. During the six months ended September 30, 2014 and September 30, 2013, approximately 83.5% and 87.8%, respectively of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended September 30, 2014, our Canada and Australia sales accounted for approximately 7.4% and 8.1%, respectively, of our total segment revenues, while during the three months ended September 30, 2013, approximately 7.2% of our total segment revenues was attributable to sales to Canada. During the six months ended September 30, 2014, our Canada and Australia sales accounted for approximately 6.6% and 7.6%, respectively, of our total segment revenues, while during the six months ended September 30, 2013, approximately 7.6% of our total segment revenues was attributable to sales to Canada.
At September 30, 2014, approximately 95.0% of our consolidated goodwill and intangible assets were located in the United States and approximately 5.0% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Goodwill	$	263,411		$	23,193	$	7,389	$	293,993
Intangible assets
Indefinite-lived	1,723,498			97,740		119,820		1,941,058
Finite-lived	196,145			1,449		25,295		222,889
Intangible assets, net	1,919,643			99,189		145,115		2,163,947
Total	$	2,183,054		$	122,382	$	152,504	$	2,457,940

Condensed_Consolidating_Financ

Condensed Consolidating Financial Statements	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Condensed Consolidating Financial Statements	'
	Condensed Consolidating Financial Statements
	As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.
	Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2014 and March 31, 2014, Condensed Consolidating Statements of Income and Comprehensive Income for the three and six months ended September 30, 2014 and 2013, and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2014 and 2013. Such consolidating information includes separate columns for:
	a)  Prestige Brands Holdings, Inc., the parent,
	b)  Prestige Brands, Inc., the issuer or the borrower,
	c)  Combined Subsidiary Guarantors,
	d)  Combined Non-Guarantor Subsidiaries, and
	e)  Elimination entries necessary to consolidate the Company and all of its subsidiaries.
	The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.
	In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1 million each, with corresponding adjustments to the investment in subsidiaries and stockholders' equity balances.
	The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company disclosed the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements relating to the second quarter of fiscal 2014. There were no changes to any of the Company's Consolidated Financial Statements.
	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	27,167		$	138,336		$	15,212		$	(710	)	$	180,005
	Other revenues	—			95			1,241			436			(508		)	1,264
	Total revenues	—			27,262			139,577			15,648			(1,218		)	181,269
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			10,426			64,812			5,767			(2,278		)	78,727
	Gross profit	—			16,836			74,765			9,881			1,060			102,542
	Operating Expenses
	Advertising and promotion	—			2,699			19,311			3,034			—			25,044
	General and administrative	1,109			3,441			20,329			2,249			—			27,128
	Depreciation and amortization	870			145			2,729			108			—			3,852
	Total operating expenses	1,979			6,285			42,369			5,391			—			56,024
	Operating income (loss)	(1,979		)	10,551			32,396			4,490			1,060			46,518
	Other (income) expense
	Interest income	(12,245		)	(16,719		)	(1,760		)	(11		)	30,720			(15		)
	Interest expense	8,629			18,208			20,333			1,758			(30,720		)	18,208
	Equity in (income) loss of subsidiaries	(17,577		)	(9,825		)	(1,870		)	—			29,272			—
	Total other (income) expense	(21,193		)	(8,336		)	16,703			1,747			29,272			18,193
	Income before income taxes	19,214			18,887			15,693			2,743			(28,212		)	28,325
	Provision for income taxes	2,751			3,262			4,976			873			—			11,862
	Net income (loss)	$	16,463		$	15,625		$	10,717		$	1,870		$	(28,212	)	$	16,463
	Comprehensive income, net of tax:
	Currency translation adjustments	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
	Total other comprehensive (loss) income	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
	Comprehensive income (loss)	$	5,633		$	4,795		$	(113	)	$	(8,960	)	$	4,278		$	5,633
	Condensed Consolidating Statements of Income and Comprehensive Income
	Six Months Ended September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	52,577		$	247,234		$	26,163		$	(1,428	)	$	324,546
	Other revenues	—			225			2,340			838			(978		)	2,425
	Total revenues	—			52,802			249,574			27,001			(2,406		)	326,971
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			19,874			115,327			9,790			(2,428		)	142,563
	Gross profit	—			32,928			134,247			17,211			22			184,408
	Operating Expenses
	Advertising and promotion	—			5,388			33,377			5,375			—			44,140
	General and administrative	2,254			5,914			29,319			6,647			—			44,134
	Depreciation and amortization	1,512			290			4,818			193			—			6,813
	Total operating expenses	3,766			11,592			67,514			12,215			—			95,087
	Operating income (loss)	(3,766		)	21,336			66,733			4,996			22			89,321
	Other (income) expense
	Interest income	(24,378		)	(30,944		)	(2,522		)	(40		)	57,837			(47		)
Interest expense	17,177			32,893			38,138			2,522			(57,837		)	32,893
Equity in (income) loss of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Total other (income) expense	(40,457		)	(18,774		)	34,705			2,482			54,890			32,846
Income before income taxes	36,691			40,110			32,028			2,514			(54,868		)	56,475
Provision (benefit) for income taxes	3,496			6,979			11,202			1,603			—			23,280
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Total other comprehensive (loss) income	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Comprehensive income (loss)	$	25,091		$	25,027		$	12,722		$	(7,193	)	$	(30,556	)	$	25,091
Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	25,237		$	132,821		$	7,449		$	—		$	165,507
Other revenues	—			67			1,431			668			(728		)	1,438
Total revenues	—			25,304			134,252			8,117			(728		)	166,945
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
Gross profit	—			15,966			72,739			4,517			—			93,222
Operating Expenses
Advertising and promotion	—			3,594			19,556			1,397			—			24,547
General and administrative	891			1,481			8,358			889			—			11,619
Depreciation and amortization	517			143			2,589			45			—			3,294
Total operating expenses	1,408			5,218			30,503			2,331			—			39,460
Operating income (loss)	(1,408		)	10,748			42,236			2,186			—			53,762
Other (income) expense
Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
Equity in (income) loss of subsidiaries	(30,344		)	(20,599		)	(1,189		)	—			52,132			—
Total other (income) expense	(34,435		)	(18,140		)	16,194			688			52,132			16,439
Income (loss) before income taxes	33,027			28,888			26,042			1,498			(52,132		)	37,323
Provision for income taxes	235			1,064			2,922			310			—			4,531
Net income (loss)	$	32,792		$	27,824		$	23,120		$	1,188		$	(52,132	)	$	32,792
Comprehensive income, net of tax:
Currency translation adjustments	1,122			1,122			1,122			1,122			(3,366		)	1,122
Total other comprehensive income (loss)	1,122			1,122			1,122			1,122			(3,366		)	1,122
Comprehensive income (loss)	$	33,914		$	28,946		$	24,242		$	2,310		$	(55,498	)	$	33,914
Condensed Consolidating Statements of Income and Comprehensive Income
Six Months Ended September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	49,386		$	249,091		$	8,672		$	—		$	307,149
Other revenues	—			135			2,294			1,102			(1,223		)	2,308
Total revenues	—			49,521			251,385			9,774			(1,223		)	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
Gross profit	—			30,725			139,883			5,638			—			176,246
Operating Expenses
Advertising and promotion	—			6,924			34,700			1,604			—			43,228
General and administrative	2,390			3,124			16,815			924			—			23,253
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Total operating expenses	3,424			10,333			56,699			2,587			—			73,043
Operating income (loss)	(3,424		)	20,392			83,184			3,051			—			103,203
Other (income) expense
Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
Equity in (income) loss of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Total other (income) expense	(57,896		)	(31,108		)	33,443			686			87,219			32,344
Income (loss) before income taxes	54,472			51,500			49,741			2,365			(87,219		)	70,859
Provision for income taxes	988			4,151			11,738			498			—			17,375
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			1,123			1,123			1,123			(3,369		)	1,123
Total other comprehensive income (loss)	1,123			1,123			1,123			1,123			(3,369		)	1,123
Comprehensive income (loss)	$	54,607		$	48,472		$	39,126		$	2,990		$	(90,588	)	$	54,607
Condensed Consolidating Balance Sheet
September 30, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
Accounts receivable, net	7			14,352			76,165			8,120			—			98,644
Inventories	—			9,666			67,420			6,777			(988		)	82,875
Deferred income tax assets	1,139			823			6,743			466			—			9,171
Prepaid expenses and other current assets	2,841			354			6,023			717			—			9,935
Total current assets	14,452			25,195			161,385			22,329			(988		)	222,373
Property and equipment, net	8,580			90			2,297			1,453			—			12,420
Goodwill	—			66,007			204,794			23,192			—			293,993
Intangible assets, net	—			192,593			1,871,933			99,421			—			2,163,947
Other long-term assets	—			32,937			—			—			—			32,937
Intercompany receivables	1,203,499			2,688,676			599,886			10,045			(4,502,106		)	—
Investment in subsidiary	1,519,129			1,213,732			79,877			—			(2,812,738		)	—
Total Assets	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long term debt	—			7,200			—			—			—			7,200
Accounts payable	2,084			9,508			42,634			4,312			—			58,538
Accrued interest payable	—			12,086			—			—			—			12,086
Other accrued liabilities	6,407			2,970			20,746			3,963			—			34,086
Total current liabilities	8,491			31,764			63,380			8,275			—			111,910
Long-term debt
Principal amount	—			1,691,400			—			—			—			1,691,400
Less unamortized discount	—			(6,289		)	—			—			—			(6,289		)
Long-term debt, net of unamortized discount	—			1,685,111			—			—			—			1,685,111
Deferred income tax liabilities	—			58,076			276,180			41			—			334,297
Other long-term liabilities	—			—			—			313			—			313
Intercompany payables	2,143,130			995,186			1,295,207			68,583			(4,502,106		)	—
Total Liabilities	2,151,621			2,770,137			1,634,767			77,212			(4,502,106		)	2,131,631
Stockholders' Equity
Preferred share rights	—			—			—			—			—			—
Common stock	524			—			—			—			—			524
Additional paid-in capital	421,574			1,280,948			1,131,578			74,031			(2,486,557		)	421,574
Treasury stock, at cost - 254 shares	(3,034		)	—			—			—			—			(3,034		)
Accumulated other comprehensive (loss) income, net of tax	(7,365		)	(7,365		)	(7,365		)	(7,365		)	22,095			(7,365		)
Retained earnings (accumulated deficit)	182,340			175,510			161,192			12,562			(349,264		)	182,340
Total Stockholders' Equity	594,039			1,449,093			1,285,405			79,228			(2,813,726		)	594,039
Total Liabilities and Stockholders' Equity	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
Condensed Consolidating Balance Sheet
March 31, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331
Accounts receivable, net	473			14,245			45,885			4,447			—			65,050
Inventories	—			14,357			46,309			5,930			(1,010		)	65,586
Deferred income tax assets	260			925			4,914			445			—			6,544
Prepaid expenses and other current assets	8,004			113			2,898			659			—			11,674
Total current assets	33,381			29,640			100,006			15,168			(1,010		)	177,185
Property and equipment, net	8,966			112			226			293			—			9,597
Goodwill	—			66,007			101,540			23,364			—			190,911
Intangible assets, net	—			192,861			1,169,943			32,013			—			1,394,817
Other long-term assets	—			23,153			—			—			—			23,153
Intercompany receivable	655,146			1,824,482			656,759			13,595			(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562			—			(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553		$	2,659		$	—		$	48,286
Accrued interest payable	—			9,626			—			—			—			9,626
Other accrued liabilities	7,728			2,117			13,443			3,158			—			26,446
Total current liabilities	12,144			19,401			46,996			5,817			—			84,358
Long-term debt
Principal amount	—			937,500			—			—			—			937,500
Less unamortized discount	—			(3,086		)	—			—			—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—			—			—			934,414
Deferred income tax liabilities	—			56,827			156,327			50			—			213,204
Other long-term liabilities	—			—			—			327			—			327
Intercompany payable	1,619,346			451,497			1,037,105			42,034			(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428			48,228			(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—			—			—			520
Additional paid-in capital	414,387			1,280,945			681,503			23,815			(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—			—			—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739			739			(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366			11,651			(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608			36,205			(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Condensed Consolidating Statement of Cash Flows
Six Months Ended September 30, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Operating Activities
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,512			290			4,818			195			—			6,815
Deferred income taxes	(879		)	1,351			11,084			(60		)	—			11,496
Amortization of deferred financing costs				2,398												2,398
Stock-based compensation costs	3,403															3,403
Amortization of debt discount				687												687
Loss on sale of assets							—			56						56
Equity in income of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	466			(107		)	(4,496		)	(4,226		)	—			(8,363		)
Inventories	—			4,691			1,857			738			(22		)	7,264
Prepaid expenses and other current assets	5,163			(241		)	(1,718		)	(90		)	—			3,114
Accounts payable	(2,332		)	1,850			(6,997		)	1,832			—			(5,647		)
Accrued liabilities	(1,321		)	3,313			(701		)	1,349			—			2,640
Net cash provided by operating activities	5,951			26,640			23,762			705			—			57,058
Investing Activities
Purchases of property and equipment	(1,127		)				(87		)	(166		)				(1,380		)
Proceeds from the sale of business	—			—			18,500			—			—			18,500
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)				—			(749,666		)
Acquisition of Hydralyte	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net				(809,157		)	731,166			77,991						—
Net cash used in investing activities	(1,127		)	(809,157		)	(87		)	(166		)	—			(810,537		)
Financing Activities
Term loan borrowings				720,000												720,000
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	2,757			—			—			—			—			2,757
Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
Fair value of shares surrendered as payment of tax withholding	(1,660		)	—			—			—			—			(1,660		)
Intercompany activity, net	(21,187		)	37,489			(18,641		)	2,339			—			—
Net cash provided by (used in) financing activities	(19,003		)	782,517			(18,641		)	2,339			—			747,212
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(316		)	—			(316		)
(Decrease) increase in cash and cash equivalents	(14,179		)	—			5,034			2,562			—			(6,583		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
Condensed Consolidating Statement of Cash Flows
Six Months Ended September 30, 2013
(In thousands)	Prestige Brands Holdings, Inc.			Prestige			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
				Brands,
				Inc.,
				the issuer
Operating Activities
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Deferred income taxes	(14		)	(642		)	5,011			—			—			4,355
Amortization of deferred financing costs	—			1,975			—			—			—			1,975
Stock-based compensation costs	2,487			—			—			—			—			2,487
Amortization of debt discount	—			798			—			—			—			798
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,323		)	(1,273		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,601			12,368			38,806			1,823			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Term loan repayments	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,347			36,122			(38,809		)	340			—			—
Net cash provided by (used in) financing activities	8,562			42,847			(38,809		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,947			—			—			2,216			—			11,163
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	23,667		$	—		$	—		$	3,166		$	—		$	26,833

Business_and_Basis_of_Presenta1

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
Revision	'
	Revision
	We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Accounts Receivable	'
	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	'
	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
Intangible Assets	'
	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.
Deferred Financing Costs	'
	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.
Revenue Recognition	'
	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	'
	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	'
	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	'
	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Business_and_Basis_of_Presenta2

Business and Basis of Presentation (Tables)	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property and Equipment	'
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Sep. 30, 2014
Insight Pharmaceuticals	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.
	(In thousands)	3-Sep-14
	Cash acquired	$	3,507
	Accounts receivable	25,784
	Inventories	23,559
	Deferred income tax assets - current	860
	Prepaids and other current assets	1,407
	Property, plant and equipment	2,308
	Goodwill	103,255
	Intangible Assets	724,374
	Total assets acquired	885,054
	Accounts payable	16,079
	Accrued expenses	8,003
	Deferred income tax liabilities - long term	107,799
	Total liabilities assumed	131,881
	Total purchase price	$	753,173
Schedule of Pro Forma Information	'
	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.
	(In thousands, except per share data)		Six Months Ended September 30, 2014
	Revenues		$	393,140
	Net income		$	37,957
	Earnings per share:
	Basic		$	0.73
	Diluted		$	0.72
	(In thousands, except per share data)		Six Months Ended September 30, 2013
	Revenues		$	389,490
	Net income		$	53,511
	Earnings per share:
	Basic		$	1.04
	Diluted		$	1.03
Hydralyte	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.
	(In thousands)	30-Apr-14
	Inventories	$	1,970
	Property, plant and equipment, net	1,267
	Goodwill	1,224
	Intangible assets, net	73,580
	Total assets acquired	78,041
	Accrued expenses	38
	Other long term liabilities	12
	Total liabilities assumed	50
	Net assets acquired	$	77,991
Care Pharma	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	1-Jul-13
	Cash acquired	$	1,546
	Accounts receivable	1,658
	Inventories	2,465
	Deferred income taxes	283
	Prepaids and other current assets	647
	Property, plant and equipment	163
	Goodwill	23,122
	Intangible assets	31,502
	Total assets acquired	61,386
	Accounts payable	1,537
	Accrued expenses	2,788
	Other long term liabilities	300
	Total liabilities assumed	4,625
	Net assets acquired	$	56,761

Accounts_Receivable_Tables

Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2014
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts receivable consist of the following:
	(In thousands)	September 30,			March 31,
		2014			2014
	Components of Accounts Receivable
	Trade accounts receivable	$	107,943		$	73,632
	Other receivables	2,176			1,360
		110,119			74,992
	Less allowances for discounts, returns and uncollectible accounts	(11,475		)	(9,942		)
	Accounts receivable, net	$	98,644		$	65,050

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consist of the following:
	(In thousands)	September 30,		March 31,
		2014		2014
	Components of Inventories
	Packaging and raw materials	$	3,929	$	3,099
	Work in process	3,456		—
	Finished goods	75,490		62,487
	Inventories	$	82,875	$	65,586

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment consist of the following:
	(In thousands)	September 30,			March 31,
		2014			2014
	Components of Property and Equipment
	Machinery	$	4,245		$	1,927
	Computer equipment and software	10,183			8,923
	Furniture and fixtures	2,703			1,858
	Leasehold improvements	4,823			4,734
		21,954			17,442
	Accumulated depreciation	(9,534		)	(7,845		)
	Property and equipment, net	$	12,420		$	9,597

Goodwill_Tables

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2014
Goodwill [Abstract]	'
Reconciliation of the Activity Affecting Goodwill	'
	A reconciliation of the activity affecting goodwill by reportable segment is as follows:
	(In thousands)	North American OTC		International OTC			Household		Consolidated
		Healthcare		Healthcare			Cleaning
	Balance — March 31, 2014	$	160,157	$	23,365		$	7,389	$	190,911
	Additions	103,254		1,224			—		104,478
	Effects of foreign currency exchange rates	—		(1,396		)	—		(1,396		)
	Balance — September 30, 2014	$	263,411	$	23,193		$	7,389	$	293,993

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2014
Intangible Assets [Abstract]	'
Reconciliation of the Activity Affecting Intangible Assets	'
	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived			Totals
		Lived			Trademarks
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
	Additions	673,180			124,774			797,954
	Reductions	—			(17,674		)	(17,674		)
	Effects of foreign currency exchange rates	(6,000		)	(95		)	(6,095		)
	Balance — September 30, 2014	1,941,058			311,745			2,252,803
	Accumulated Amortization
	Balance — March 31, 2014	—			83,801			83,801
	Additions	—			5,064			5,064
	Effects of foreign currency exchange rates	—			(9		)	(9		)
	Balance — September 30, 2014	—			88,856			88,856
	Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
	Intangible Assets, net by Reportable Segment:
	North American OTC Healthcare	$	1,723,498		$	196,145		$	1,919,643
	International OTC Healthcare	97,740			1,449			99,189
	Household Cleaning	119,820			25,295			145,115
	Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
Schedule of Expected Amortization Expense	'
	At September 30, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2015 (Remaining six months ending March 31, 2015)		$	7,740
	2016		15,554
	2017		15,554
	2018		15,554
	2019		15,554
	Thereafter		152,933
			$	222,889

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other accrued liabilities consist of the following:
	(In thousands)	September 30,		March 31,
		2014		2014
	Accrued marketing costs	$	16,187	$	11,812
	Accrued compensation costs	5,129		6,232
	Accrued broker commissions	851		1,019
	Income taxes payable	1,186		1,854
	Accrued professional fees	2,344		2,002
	Deferred rent	1,109		1,258
	Accrued production costs	3,364		1,506
	Other accrued liabilities	3,916		763
		$	34,086	$	26,446

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt	'
	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	September 30,			March 31,
		2014			2014
	2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
	2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
	2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	262,500			287,500
	2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	720,000			—
	2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
		1,698,600			937,500
	Current portion of long-term debt	7,200			—
		1,691,400			937,500
	Less: unamortized discount	(6,289		)	(3,086		)
	Long-term debt, net of unamortized discount	$	1,685,111		$	934,414
Aggregate Future Principal Payments	'
	As of September 30, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2015 (remaining six months ending March 31, 2015)	$	3,600
	2016	7,200
	2017	73,300
	2018	7,200
	2019	269,700
	Thereafter	1,337,600
		$	1,698,600

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income (Tables)	6 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
	The table below presents accumulated other comprehensive (loss) income (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.
	AOCI consisted of the following at September 30, 2014 and March 31, 2014:
		September 30,			March 31,
	(In thousands)	2014			2014
	Components of Accumulated Other Comprehensive (Loss) Income
	Cumulative translation adjustment	$	(7,365	)	$	739
	Total accumulated other comprehensive (loss) income, net of tax	$	(7,365	)	$	739

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Earnings Per Share	'
	The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended September 30,				Six Months Ended September 30,
	(In thousands, except per share data)	2014		2013		2014		2013
	Numerator
	Net income	$	16,463	$	32,792	$	33,195	$	53,484
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	52,088		51,463		52,023		51,343
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	506		756		541		787
	Denominator for diluted earnings per share	52,594		52,219		52,564		52,130
	Earnings per Common Share:
	Basic net earnings per share	$	0.32	$	0.64	$	0.64	$	1.04
	Diluted net earnings per share	$	0.31	$	0.63	$	0.63	$	1.03

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Restricted Shares	'
	A summary of the Company's restricted shares granted under the Plan is presented below:
					Weighted-
		Shares			Average
		(in thousands)			Grant-Date
	Restricted Shares				Fair Value
	Six months ended September 30, 2013
	Vested and nonvested at March 31, 2013	421.3			$	11.01
	Granted	120.6			30.19
	Vested and issued	(54.7	)		8.11
	Forfeited	(3.6	)		13.24
	Vested and nonvested at September 30, 2013	483.6			16.11
	Vested at September 30, 2013	83.1			9.63
	Six months ended September 30, 2014:
	Vested and nonvested at March 31, 2014	437.5			$	16.76
	Granted	104.4			33.3
	Vested and issued	(120.7	)		13.34
	Forfeited	(14.4	)		20.78
	Vested and nonvested at September 30, 2014	406.8			21.88
	Vested at September 30, 2014	76.6			11.62
Stock Options, Valuation Assumptions	'
		Six Months Ended September 30,
		2014				2013
	Expected volatility	47.3		%		48		%
	Expected dividends	$	—			$	—
	Expected term in years	6				6
	Risk-free rate	2.2		%		1.3		%
Stock Option Activity	'
	A summary of option activity under the Plan is as follows:
					Weighted-				Weighted-	Aggregate
					Average				Average	Intrinsic
		Shares			Exercise				Remaining	Value
		(in thousands)			Price				Contractual	(in thousands)
	Options								Term
	Six months ended September 30, 2013:
	Outstanding at March 31, 2013	1,386.40			$	10.43
	Granted	227.7			29.94
	Exercised	(539.4	)		9.54
	Forfeited or expired	(8.0	)		13.24
	Outstanding at September 30, 2013	1,066.70			15.02				6.5	$	16,110
	Exercisable at September 30, 2013	225.5			11.42				7.7	4,216
	Six months ended September 30, 2014:
	Outstanding at March 31, 2014	994.9			$	15.24
	Granted	307.5			33.5
	Exercised	(284.4	)		9.7
	Forfeited or expired	(32.5	)		25.61
	Outstanding at September 30, 2014	985.5			22.19				8	$	10,364
	Exercisable at September 30, 2014	416			14.31				6.8	7,514

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	The following summarizes future minimum lease payments for our operating leases as of September 30, 2014:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2015 (Remaining six months ending March 31, 2015)	$	859	$	344	$	1,203
	2016	1,612		311		1,923
	2017	1,772		77		1,849
	2018	1,856		—		1,856
	2019	1,864		—		1,864
	Thereafter	2,465		—		2,465
		$	10,428	$	732	$	11,160
Unrecorded Unconditional Purchase Obligations Disclosure	'
	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2015 (Remaining six months ending March 31, 2015)	$	549
	2016	1,074
	2017	1,044
	2018	1,013
	2019	982
	Thereafter	560
		$	5,222

Business_Segments_Tables

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Information about our Operating and Reportable Segments	'
	The tables below summarize information about our reportable segments.
		Three Months Ended September 30, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	138,138		$	17,331	$	25,246	$	180,715
	Elimination of intersegment revenues	(710		)	—		—		(710		)
	Third-party segment revenues	137,428			17,331		25,246		180,005
	Other revenues	150			23		1,091		1,264
	Total segment revenues	137,578			17,354		26,337		181,269
	Cost of sales	52,185			6,595		19,947		78,727
	Gross profit	85,393			10,759		6,390		102,542
	Advertising and promotion	21,442			3,035		567		25,044
	Contribution margin	$	63,951		$	7,724	$	5,823	77,498
	Other operating expenses								30,980
	Operating income								46,518
	Other expense								18,193
	Income before income taxes								28,325
	Provision for income taxes								11,862
	Net income								$	16,463
		Six Months Ended September 30, 2014
	(In thousands)	North			International		Household		Consolidated
		American			OTC		Cleaning
		OTC			Healthcare
		Healthcare
	Gross segment revenues	$	249,112		$	31,022	$	45,839	$	325,973
	Elimination of intersegment revenues	(1,427		)	—		—		(1,427		)
	Third-party segment revenues	247,685			31,022		45,839		324,546
	Other revenues	327			58		2,040		2,425
	Total segment revenues	248,012			31,080		47,879		326,971
	Cost of sales	94,526			11,679		36,358		142,563
	Gross profit	153,486			19,401		11,521		184,408
	Advertising and promotion	37,794			5,375		971		44,140
	Contribution margin	$	115,692		$	14,026	$	10,550	140,268
	Other operating expenses								50,947
	Operating income								89,321
	Other expense								32,846
	Income before income taxes								56,475
	Provision for income taxes								23,280
	Net income								$	33,195
		Three Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	132,944		$	9,008	$	24,374	$	166,326
	Elimination of intersegment revenues	(819		)	—		—		(819		)
	Third-party segment revenues	132,125			9,008		24,374		165,507
	Other revenues	150			7		1,281		1,438
	Total segment revenues	132,275			9,015		25,655		166,945
	Cost of sales	50,987			4,338		18,398		73,723
	Gross profit	81,288			4,677		7,257		93,222
	Advertising and promotion	22,547			1,446		554		24,547
	Contribution margin	$	58,741		$	3,231	$	6,703	68,675
	Other operating expenses								14,913
	Operating income								53,762
	Other expense								16,439
	Income before income taxes								37,323
	Provision for income taxes								4,531
	Net income								$	32,792
		Six Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	251,880		$	12,422	$	43,666	$	307,968
	Elimination of intersegment revenues	(819		)	—		—		(819		)
	Third-party segment revenues	251,061			12,422		43,666		307,149
Other revenues	300			14		1,994		2,308
Total segment revenues	251,361			12,436		45,660		309,457
Cost of sales	94,533			5,803		32,875		133,211
Gross profit	156,828			6,633		12,785		176,246
Advertising and promotion	40,097			1,710		1,421		43,228
Contribution margin	$	116,731		$	4,923	$	11,364	133,018
Other operating expenses								29,815
Operating income								103,203
Other expense								32,344
Income before income taxes								70,859
Provision for income taxes								17,375
Net income								$	53,484
Information about our Revenues from Similar Product Groups	'
	The tables below summarize information about our segment revenues from similar product groups.
		Three Months Ended September 30, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	29,072		$	792	$	—	$	29,864
	Cough & Cold	24,771			5,460		—		30,231
	Women's Health	9,119			658		—		9,777
	Gastrointestinal	20,896			5,598		—		26,494
	Eye & Ear Care	21,405			4,028		—		25,433
	Dermatologicals	17,459			687		—		18,146
	Oral Care	12,934			127		—		13,061
	Other OTC	1,922			4		—		1,926
	Household Cleaning	—			—		26,337		26,337
	Total segment revenues	$	137,578		$	17,354	$	26,337	$	181,269
		Six Months Ended September 30, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	54,103		$	1,457	$	—	$	55,560
	Cough & Cold	44,814			10,259		—		55,073
	Women's Health	9,487			1,176				10,663
	Gastrointestinal	41,534			8,096		—		49,630
	Eye & Ear Care	42,130			8,670		—		50,800
	Dermatologicals	29,720			1,229		—		30,949
	Oral Care	23,121			189		—		23,310
	Other OTC	3,103			4		—		3,107
	Household Cleaning	—			—		47,879		47,879
	Total segment revenues	$	248,012		$	31,080	$	47,879	$	326,971
		Three Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	29,343		$	698	$	—	$	30,041
	Cough & Cold	28,695			5,023		—		33,718
	Women's Health	501			633		—		1,134
	Gastrointestinal	21,695			301		—		21,996
	Eye & Ear Care	19,378			1,625		—		21,003
	Dermatologicals	17,716			605		—		18,321
	Oral Care	13,028			130		—		13,158
	Other OTC	1,919			—		—		1,919
	Household Cleaning	—			—		25,655		25,655
	Total segment revenues	$	132,275		$	9,015	$	25,655	$	166,945
		Six Months Ended September 30, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	57,479		$	727	$	—	$	58,206
	Cough & Cold	49,193			6,006		—		55,199
	Women's Health	988			633		—		1,621
	Gastrointestinal	43,453			312		—		43,765
	Eye & Ear Care	39,710			3,885		—		43,595
	Dermatologicals	32,347			696		—		33,043
	Oral Care	24,114			177		—		24,291
	Other OTC	4,077			—		—		4,077
	Household Cleaning	—			—		45,660		45,660
	Total segment revenues	$	251,361		$	12,436	$	45,660	$	309,457
Allocation of Long-Term Assets to Segments	'
	At September 30, 2014, approximately 95.0% of our consolidated goodwill and intangible assets were located in the United States and approximately 5.0% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Goodwill	$	263,411		$	23,193	$	7,389	$	293,993
	Intangible assets
	Indefinite-lived	1,723,498			97,740		119,820		1,941,058
	Finite-lived	196,145			1,449		25,295		222,889
	Intangible assets, net	1,919,643			99,189		145,115		2,163,947
	Total	$	2,183,054		$	122,382	$	152,504	$	2,457,940

Condensed_Consolidating_Financ1

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Condensed Consolidating Statements of Income and Comprehensive Income	'
	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	27,167		$	138,336		$	15,212		$	(710	)	$	180,005
	Other revenues	—			95			1,241			436			(508		)	1,264
	Total revenues	—			27,262			139,577			15,648			(1,218		)	181,269
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			10,426			64,812			5,767			(2,278		)	78,727
	Gross profit	—			16,836			74,765			9,881			1,060			102,542
	Operating Expenses
	Advertising and promotion	—			2,699			19,311			3,034			—			25,044
	General and administrative	1,109			3,441			20,329			2,249			—			27,128
	Depreciation and amortization	870			145			2,729			108			—			3,852
	Total operating expenses	1,979			6,285			42,369			5,391			—			56,024
	Operating income (loss)	(1,979		)	10,551			32,396			4,490			1,060			46,518
	Other (income) expense
	Interest income	(12,245		)	(16,719		)	(1,760		)	(11		)	30,720			(15		)
	Interest expense	8,629			18,208			20,333			1,758			(30,720		)	18,208
	Equity in (income) loss of subsidiaries	(17,577		)	(9,825		)	(1,870		)	—			29,272			—
	Total other (income) expense	(21,193		)	(8,336		)	16,703			1,747			29,272			18,193
	Income before income taxes	19,214			18,887			15,693			2,743			(28,212		)	28,325
	Provision for income taxes	2,751			3,262			4,976			873			—			11,862
	Net income (loss)	$	16,463		$	15,625		$	10,717		$	1,870		$	(28,212	)	$	16,463
	Comprehensive income, net of tax:
	Currency translation adjustments	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
	Total other comprehensive (loss) income	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
	Comprehensive income (loss)	$	5,633		$	4,795		$	(113	)	$	(8,960	)	$	4,278		$	5,633
	Condensed Consolidating Statements of Income and Comprehensive Income
	Six Months Ended September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	52,577		$	247,234		$	26,163		$	(1,428	)	$	324,546
	Other revenues	—			225			2,340			838			(978		)	2,425
	Total revenues	—			52,802			249,574			27,001			(2,406		)	326,971
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			19,874			115,327			9,790			(2,428		)	142,563
	Gross profit	—			32,928			134,247			17,211			22			184,408
	Operating Expenses
	Advertising and promotion	—			5,388			33,377			5,375			—			44,140
	General and administrative	2,254			5,914			29,319			6,647			—			44,134
	Depreciation and amortization	1,512			290			4,818			193			—			6,813
	Total operating expenses	3,766			11,592			67,514			12,215			—			95,087
	Operating income (loss)	(3,766		)	21,336			66,733			4,996			22			89,321
	Other (income) expense
	Interest income	(24,378		)	(30,944		)	(2,522		)	(40		)	57,837			(47		)
	Interest expense	17,177			32,893			38,138			2,522			(57,837		)	32,893
	Equity in (income) loss of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
	Total other (income) expense	(40,457		)	(18,774		)	34,705			2,482			54,890			32,846
	Income before income taxes	36,691			40,110			32,028			2,514			(54,868		)	56,475
	Provision (benefit) for income taxes	3,496			6,979			11,202			1,603			—			23,280
	Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
	Comprehensive income, net of tax:
	Currency translation adjustments	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
	Total other comprehensive (loss) income	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
	Comprehensive income (loss)	$	25,091		$	25,027		$	12,722		$	(7,193	)	$	(30,556	)	$	25,091
	Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	25,237		$	132,821		$	7,449		$	—		$	165,507
Other revenues	—			67			1,431			668			(728		)	1,438
Total revenues	—			25,304			134,252			8,117			(728		)	166,945
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
Gross profit	—			15,966			72,739			4,517			—			93,222
Operating Expenses
Advertising and promotion	—			3,594			19,556			1,397			—			24,547
General and administrative	891			1,481			8,358			889			—			11,619
Depreciation and amortization	517			143			2,589			45			—			3,294
Total operating expenses	1,408			5,218			30,503			2,331			—			39,460
Operating income (loss)	(1,408		)	10,748			42,236			2,186			—			53,762
Other (income) expense
Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
Equity in (income) loss of subsidiaries	(30,344		)	(20,599		)	(1,189		)	—			52,132			—
Total other (income) expense	(34,435		)	(18,140		)	16,194			688			52,132			16,439
Income (loss) before income taxes	33,027			28,888			26,042			1,498			(52,132		)	37,323
Provision for income taxes	235			1,064			2,922			310			—			4,531
Net income (loss)	$	32,792		$	27,824		$	23,120		$	1,188		$	(52,132	)	$	32,792
Comprehensive income, net of tax:
Currency translation adjustments	1,122			1,122			1,122			1,122			(3,366		)	1,122
Total other comprehensive income (loss)	1,122			1,122			1,122			1,122			(3,366		)	1,122
Comprehensive income (loss)	$	33,914		$	28,946		$	24,242		$	2,310		$	(55,498	)	$	33,914
Condensed Consolidating Statements of Income and Comprehensive Income
Six Months Ended September 30, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	49,386		$	249,091		$	8,672		$	—		$	307,149
Other revenues	—			135			2,294			1,102			(1,223		)	2,308
Total revenues	—			49,521			251,385			9,774			(1,223		)	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
Gross profit	—			30,725			139,883			5,638			—			176,246
Operating Expenses
Advertising and promotion	—			6,924			34,700			1,604			—			43,228
General and administrative	2,390			3,124			16,815			924			—			23,253
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Total operating expenses	3,424			10,333			56,699			2,587			—			73,043
Operating income (loss)	(3,424		)	20,392			83,184			3,051			—			103,203
Other (income) expense
Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
Equity in (income) loss of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Total other (income) expense	(57,896		)	(31,108		)	33,443			686			87,219			32,344
Income (loss) before income taxes	54,472			51,500			49,741			2,365			(87,219		)	70,859
Provision for income taxes	988			4,151			11,738			498			—			17,375
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			1,123			1,123			1,123			(3,369		)	1,123
Total other comprehensive income (loss)	1,123			1,123			1,123			1,123			(3,369		)	1,123
Comprehensive income (loss)	$	54,607		$	48,472		$	39,126		$	2,990		$	(90,588	)	$	54,607
Condensed Consolidating Balance Sheet	'
	Condensed Consolidating Balance Sheet
	September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
	Accounts receivable, net	7			14,352			76,165			8,120			—			98,644
	Inventories	—			9,666			67,420			6,777			(988		)	82,875
	Deferred income tax assets	1,139			823			6,743			466			—			9,171
	Prepaid expenses and other current assets	2,841			354			6,023			717			—			9,935
	Total current assets	14,452			25,195			161,385			22,329			(988		)	222,373
	Property and equipment, net	8,580			90			2,297			1,453			—			12,420
	Goodwill	—			66,007			204,794			23,192			—			293,993
	Intangible assets, net	—			192,593			1,871,933			99,421			—			2,163,947
	Other long-term assets	—			32,937			—			—			—			32,937
	Intercompany receivables	1,203,499			2,688,676			599,886			10,045			(4,502,106		)	—
	Investment in subsidiary	1,519,129			1,213,732			79,877			—			(2,812,738		)	—
	Total Assets	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
	Liabilities and Stockholders' Equity
	Current liabilities
	Current portion of long term debt	—			7,200			—			—			—			7,200
	Accounts payable	2,084			9,508			42,634			4,312			—			58,538
	Accrued interest payable	—			12,086			—			—			—			12,086
	Other accrued liabilities	6,407			2,970			20,746			3,963			—			34,086
	Total current liabilities	8,491			31,764			63,380			8,275			—			111,910
	Long-term debt
	Principal amount	—			1,691,400			—			—			—			1,691,400
	Less unamortized discount	—			(6,289		)	—			—			—			(6,289		)
	Long-term debt, net of unamortized discount	—			1,685,111			—			—			—			1,685,111
	Deferred income tax liabilities	—			58,076			276,180			41			—			334,297
	Other long-term liabilities	—			—			—			313			—			313
	Intercompany payables	2,143,130			995,186			1,295,207			68,583			(4,502,106		)	—
	Total Liabilities	2,151,621			2,770,137			1,634,767			77,212			(4,502,106		)	2,131,631
	Stockholders' Equity
	Preferred share rights	—			—			—			—			—			—
	Common stock	524			—			—			—			—			524
	Additional paid-in capital	421,574			1,280,948			1,131,578			74,031			(2,486,557		)	421,574
	Treasury stock, at cost - 254 shares	(3,034		)	—			—			—			—			(3,034		)
	Accumulated other comprehensive (loss) income, net of tax	(7,365		)	(7,365		)	(7,365		)	(7,365		)	22,095			(7,365		)
	Retained earnings (accumulated deficit)	182,340			175,510			161,192			12,562			(349,264		)	182,340
	Total Stockholders' Equity	594,039			1,449,093			1,285,405			79,228			(2,813,726		)	594,039
	Total Liabilities and Stockholders' Equity	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
	Condensed Consolidating Balance Sheet
	March 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331
	Accounts receivable, net	473			14,245			45,885			4,447			—			65,050
	Inventories	—			14,357			46,309			5,930			(1,010		)	65,586
	Deferred income tax assets	260			925			4,914			445			—			6,544
	Prepaid expenses and other current assets	8,004			113			2,898			659			—			11,674
	Total current assets	33,381			29,640			100,006			15,168			(1,010		)	177,185
	Property and equipment, net	8,966			112			226			293			—			9,597
	Goodwill	—			66,007			101,540			23,364			—			190,911
	Intangible assets, net	—			192,861			1,169,943			32,013			—			1,394,817
	Other long-term assets	—			23,153			—			—			—			23,153
Intercompany receivable	655,146			1,824,482			656,759			13,595			(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562			—			(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553		$	2,659		$	—		$	48,286
Accrued interest payable	—			9,626			—			—			—			9,626
Other accrued liabilities	7,728			2,117			13,443			3,158			—			26,446
Total current liabilities	12,144			19,401			46,996			5,817			—			84,358
Long-term debt
Principal amount	—			937,500			—			—			—			937,500
Less unamortized discount	—			(3,086		)	—			—			—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—			—			—			934,414
Deferred income tax liabilities	—			56,827			156,327			50			—			213,204
Other long-term liabilities	—			—			—			327			—			327
Intercompany payable	1,619,346			451,497			1,037,105			42,034			(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428			48,228			(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—			—			—			520
Additional paid-in capital	414,387			1,280,945			681,503			23,815			(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—			—			—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739			739			(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366			11,651			(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608			36,205			(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Condensed Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows
	Six Months Ended September 30, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Operating Activities
	Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	1,512			290			4,818			195			—			6,815
	Deferred income taxes	(879		)	1,351			11,084			(60		)	—			11,496
	Amortization of deferred financing costs				2,398												2,398
	Stock-based compensation costs	3,403															3,403
	Amortization of debt discount				687												687
	Loss on sale of assets							—			56						56
	Equity in income of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
	Changes in operating assets and liabilities, net of effects from acquisitions:
	Accounts receivable	466			(107		)	(4,496		)	(4,226		)	—			(8,363		)
	Inventories	—			4,691			1,857			738			(22		)	7,264
	Prepaid expenses and other current assets	5,163			(241		)	(1,718		)	(90		)	—			3,114
	Accounts payable	(2,332		)	1,850			(6,997		)	1,832			—			(5,647		)
	Accrued liabilities	(1,321		)	3,313			(701		)	1,349			—			2,640
	Net cash provided by operating activities	5,951			26,640			23,762			705			—			57,058
	Investing Activities
	Purchases of property and equipment	(1,127		)				(87		)	(166		)				(1,380		)
	Proceeds from the sale of business	—			—			18,500			—			—			18,500
	Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)				—			(749,666		)
	Acquisition of Hydralyte	—			—			—			(77,991		)	—			(77,991		)
	Intercompany activity, net				(809,157		)	731,166			77,991						—
	Net cash used in investing activities	(1,127		)	(809,157		)	(87		)	(166		)	—			(810,537		)
	Financing Activities
	Term loan borrowings				720,000												720,000
	Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
	Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
	Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
	Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
	Proceeds from exercise of stock options	2,757			—			—			—			—			2,757
	Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
	Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
	Fair value of shares surrendered as payment of tax withholding	(1,660		)	—			—			—			—			(1,660		)
	Intercompany activity, net	(21,187		)	37,489			(18,641		)	2,339			—			—
	Net cash provided by (used in) financing activities	(19,003		)	782,517			(18,641		)	2,339			—			747,212
	Effect of exchange rate changes on cash and cash equivalents	—			—			—			(316		)	—			(316		)
	(Decrease) increase in cash and cash equivalents	(14,179		)	—			5,034			2,562			—			(6,583		)
	Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
	Cash and cash equivalents - end of period	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
	Condensed Consolidating Statement of Cash Flows
	Six Months Ended September 30, 2013
	(In thousands)	Prestige Brands Holdings, Inc.			Prestige			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
					Brands,
					Inc.,
					the issuer
	Operating Activities
	Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	1,034			285			5,184			59			—			6,562
	Deferred income taxes	(14		)	(642		)	5,011			—			—			4,355
	Amortization of deferred financing costs	—			1,975			—			—			—			1,975
	Stock-based compensation costs	2,487			—			—			—			—			2,487
	Amortization of debt discount	—			798			—			—			—			798
	Gain on sale of assets	—			—			(3		)	—			—			(3		)
	Equity in income of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
	Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,323		)	(1,273		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,601			12,368			38,806			1,823			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Term loan repayments	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,347			36,122			(38,809		)	340			—			—
Net cash provided by (used in) financing activities	8,562			42,847			(38,809		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,947			—			—			2,216			—			11,163
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	23,667		$	—		$	—		$	3,166		$	—		$	26,833

Business_and_Basis_of_Presenta3

Business and Basis of Presentation (Property and Equipment) (Details)	6 Months Ended
	Sep. 30, 2014
Machinery	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'5 years
Computer equipment and software	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'3 years
Furniture and fixtures	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'7 years
Leasehold improvements	'
Property, Plant and Equipment [Line Items]	'
Property and equipment, useful lives	'	[1]
[1]	Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Business_and_Basis_of_Presenta4

Business and Basis of Presentation (Intangible Assets) (Details)	6 Months Ended
	Sep. 30, 2014
Minimum	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets, useful lives	'3 years
Maximum	'
Finite-Lived Intangible Assets [Line Items]	'
Intangible assets, useful lives	'30 years

Business_and_Basis_of_Presenta5

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'
Ownership percentage	100.00%	'	100.00%	'
Term of original maturities, cash equivalents, up to and including	'	'	'3 months	'
Shipping, warehousing and handling costs	$9.40	$9.10	$17.10	$15.70

Acquisitions_Allocation_of_Ass

Acquisitions Allocation of Assets Acquired and Liabilities Assumed(Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 03, 2014	Apr. 30, 2014	Jul. 02, 2013
In Thousands, unless otherwise specified			Insight Pharmaceuticals	Hydralyte	Care Pharma
Purchase Price	'	'	'	'	'
Cash acquired	'	'	$3,507	'	$1,546
Accounts receivable	'	'	25,784	'	1,658
Inventories	'	'	23,559	1,970	2,465
Deferred income tax assets - current	'	'	860	'	283
Prepaids and other current assets	'	'	1,407	'	647
Property, plant and equipment	'	'	2,308	1,267	163
Goodwill	293,993	190,911	103,255	1,224	23,122
Intangible Assets	'	'	724,374	73,580	31,502
Total assets acquired	'	'	885,054	78,041	61,386
Accounts payable	'	'	16,079	'	1,537
Accrued expenses	'	'	8,003	38	2,788
Deferred income tax liabilities - long term	'	'	107,799	'	'
Other long term liabilities	'	'	'	12	300
Total liabilities assumed	'	'	131,881	50	4,625
Net assets acquired	'	'	$753,173	$77,991	$56,761

Acquisitions_Narrative_Details

Acquisitions Narrative (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 03, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 03, 2014

Sep. 03, 2014

Sep. 03, 2014

Sep. 03, 2014

Apr. 30, 2014

Sep. 30, 2014

Jul. 02, 2013

Insight Pharmaceuticals

Insight Pharmaceuticals

Insight Pharmaceuticals

Insight Pharmaceuticals

Insight Pharmaceuticals

Insight Pharmaceuticals

Insight Pharmaceuticals

Hydralyte

Care Pharma

Care Pharma

brand

Intangible assets

Inventory

Property, plant and equipment

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of acquisition

'

'

'

'

'

$753,200,000

'

'

'

'

'

'

'

'

'

Number of pharmaceutical brands acquired as a result of acquisition

'

'

'

'

'

27

'

'

'

'

'

'

'

'

'

Number of brands sold

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

Non-amortizable intangible assets

'

'

'

'

'

'

'

'

599,600,000

'

'

'

'

'

29,800,000

Amortizable intangible assets

'

'

'

'

'

'

'

'

124,800,000

'

'

'

'

'

1,700,000

Purchased amortizable intangible assets, weighted average useful life

'

'

'

'

'

'

'16 years 2 months 12 days

'

'

'

'

'

'

'15 years 1 month 6 days

'

Purchased amortizable intangible assets, weighted average remaining period

'

'

'14 years 6 months

'

'

'

'16 years 1 month 12 days

'

'

'

'

'

'

'13 years 0 months 22 days

'

Goodwill

293,993,000

'

293,993,000

'

190,911,000

'

'

'

103,255,000

'

'

'

1,224,000

'

23,122,000

Revenues of acquired business

'

'

'

'

'

'

12,700,000

12,700,000

'

'

'

'

'

'

'

Net income

16,463,000

32,792,000

33,195,000

53,484,000

'

'

2,000,000

3,200,000

'

'

'

'

'

'

'

Value of assets sold on acquisition date, excluded from purchase price

'

'

'

'

'

'

'

'

$18,500,000

$17,700,000

$600,000

$200,000

'

'

'

Acquisitions_Pro_Forma_Informa

Acquisitions Pro Forma Information (Details) (Insight Pharmaceuticals, USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Insight Pharmaceuticals	'	'
Business Acquisition [Line Items]	'	'
Revenues	$393,140	$389,490
Net income	$37,957	$53,511
Earnings per share:	'	'
Basic EPS (in dollars per share)	$0.73	$1.04
Diluted EPS (in dollars per share)	$0.72	$1.03

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$110,119	$74,992
Less allowances for discounts, returns and uncollectible accounts	-11,475	-9,942
Accounts receivable, net	98,644	65,050
Trade Accounts Receivable	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	107,943	73,632
Other Receivables	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable, gross	$2,176	$1,360

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Inventory Disclosure [Abstract]	'	'
Packaging and raw materials	$3,929,000	$3,099,000
Work in process	3,456,000	0
Finished goods	75,490,000	62,487,000
Inventories	82,875,000	65,586,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$4,800,000	$1,100,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	$21,954,000	'	$21,954,000	'	$17,442,000
Accumulated depreciation	-9,534,000	'	-9,534,000	'	-7,845,000
Property and equipment, net	12,420,000	'	12,420,000	'	9,597,000
Depreciation	900,000	500,000	1,600,000	1,100,000	'
Machinery	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	4,245,000	'	4,245,000	'	1,927,000
Computer equipment and software	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	10,183,000	'	10,183,000	'	8,923,000
Furniture and fixtures	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	2,703,000	'	2,703,000	'	1,858,000
Leasehold improvements	'	'	'	'	'
Components of Property and Equipment	'	'	'	'	'
Property and equipment, gross	$4,823,000	'	$4,823,000	'	$4,734,000

Goodwill_Details

Goodwill (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 03, 2014	Apr. 30, 2014
	business	North American OTC Healthcare	International OTC Healthcare	Household Cleaning	Insight Pharmaceuticals	Hydralyte
Goodwill [Roll Forward]	'	'	'	'	'	'
Balance — March 31, 2014	$190,911	$160,157	$23,365	$7,389	$103,255	$1,224
Additions	104,478	103,254	1,224	0	'	'
Effects of foreign currency exchange rates	-1,396	0	-1,396	0	'	'
Balance — September 30, 2014	$293,993	$263,411	$23,193	$7,389	$103,255	$1,224
Number of acquisitions	2	'	'	'	'	'

Intangible_Assets_Schedule_of_

Intangible Assets Schedule of Reconciliation of Activity Affecting Intangible Assets (Details) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Mar. 31, 2014
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite Lived Trademarks, ending balance	$1,941,058	$1,941,058	'
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, additions	2,800	5,064	'
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	'	-9	'
Intangible Assets, Gross [Abstract]	'	'	'
Totals, gross, beginning balance	'	1,478,618	'
Totals, additions	'	797,954	'
Totals, reductions	'	-17,674	'
Totals, effects of foreign currency exchange rate	'	-6,095	'
Totals, gross, ending balance	2,252,803	2,252,803	'
Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Totals, accumulated amortization, beginning balance	'	83,801	'
Intangible assets, accumulated amortization, additions	2,800	5,064	'
Totals, accumulated amortization, ending balance	88,856	88,856	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	222,889	222,889	'
Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net (excluding goodwill)	2,163,947	2,163,947	1,394,817
North American OTC Healthcare	'	'	'
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite Lived Trademarks, ending balance	1,723,498	1,723,498	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	196,145	196,145	'
Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net (excluding goodwill)	1,919,643	1,919,643	'
International OTC Healthcare	'	'	'
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite Lived Trademarks, ending balance	97,740	97,740	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	1,449	1,449	'
Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net (excluding goodwill)	99,189	99,189	'
Household Cleaning	'	'	'
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite Lived Trademarks, ending balance	119,820	119,820	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	25,295	25,295	'
Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net (excluding goodwill)	145,115	145,115	'
Indefinite Lived Trademarks	'	'	'
Indefinite-Lived Intangible Assets [Abstract]	'	'	'
Indefinite Lived Trademarks, beginning balance	'	1,273,878	'
Indefinite-lived Intangible Assets Acquired	'	673,180	'
Indefinite Lived Trademarks, reductions	'	0	'
Indefinite Lived Trademarks, effects of foreign currency exchange rate	'	-6,000	'
Indefinite Lived Trademarks, ending balance	1,941,058	1,941,058	'
Finite Lived Trademarks	'	'	'
Finite-Lived Intangible Assets, Gross [Abstract]	'	'	'
Finite Lived Trademarks, beginning balance	'	204,740	'
Finite Lived Trademarks, additions	'	124,774	'
Finite Lived Trademarks, reductions	'	-17,674	'
Finite Lived Trademarks, effects of foreign currency exchange rate	'	-95	'
Finite Lived Trademarks, ending balance	311,745	311,745	'
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Finite Lived Trademarks, accumulated amortization, beginning balance	'	83,801	'
Intangible assets, accumulated amortization, additions	'	5,064	'
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates	'	-9	'
Finite Lived Trademarks, accumulated amortization, ending balance	88,856	88,856	'
Intangible Assets, Accumulated Amortization [Abstract]	'	'	'
Intangible assets, accumulated amortization, additions	'	5,064	'
Finite-Lived Intangible Assets, Net [Abstract]	'	'	'
Intangible assets, net	$222,889	$222,889	'

Intangible_Assets_Narrative_De

Intangible Assets Narrative (Details) (USD $)	3 Months Ended	6 Months Ended			0 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 03, 2014	Sep. 30, 2014	Sep. 03, 2014	Apr. 30, 2014
		business	Minimum	Maximum	Insight Pharmaceuticals	Insight Pharmaceuticals	Insight Pharmaceuticals	Hydralyte
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'
Number of acquisitions	'	2	'	'	'	'	'	'
Intangible Assets	'	'	'	'	'	'	$724,374,000	$73,580,000
Acquired intangible assets sold on acquisition date	'	'	'	'	17,700,000	'	'	'
Weighted average remaining life for finite-lived intangible assets	'	'14 years 6 months	'	'	'	'16 years 1 month 12 days	'	'
Amortization of Intangible Assets	$2,800,000	$5,064,000	'	'	'	'	'	'
Intangible assets, useful lives	'	'	'3 years	'30 years	'	'	'	'

Intangible_Assets_Expected_Amo

Intangible Assets Expected Amortization Expense (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'
2015 (Remaining six months ending March 31, 2015)	$7,740
2016	15,554
2017	15,554
2018	15,554
2019	15,554
Thereafter	152,933
Intangible assets, net	$222,889

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued marketing costs	$16,187	$11,812
Accrued compensation costs	5,129	6,232
Accrued broker commissions	851	1,019
Income taxes payable	1,186	1,854
Accrued professional fees	2,344	2,002
Deferred rent	1,109	1,258
Accrued production costs	3,364	1,506
Other accrued liabilities	3,916	763
Total other accrued liabilities	$34,086	$26,446

LongTerm_Debt_2012_Senior_Note

Long-Term Debt (2012 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]	'	'
Percentage of subsidiary owned	100.00%	100.00%
2012 Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Debt issuance costs capitalized	'	12,600,000
Senior Notes | 2012 Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	'	250,000,000
Debt instrument, stated interest rate	'	8.13%

LongTerm_Debt_2012_Term_Loan_a

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)

Sep. 30, 2014

Mar. 31, 2014

Dec. 17, 2013

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Sep. 30, 2014

Mar. 31, 2013

Feb. 21, 2013

Sep. 03, 2014

Sep. 30, 2014

Sep. 03, 2014

Jan. 31, 2012

Jan. 31, 2012

Sep. 30, 2013

Sep. 30, 2014

Sep. 03, 2014

Feb. 21, 2013

Sep. 03, 2014

Sep. 03, 2014

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Term Loan and ABL Revolver 2012

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term B-2

Term B-2

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

LIBOR

LIBOR

LIBOR

LIBOR

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Base Rate

Minimum

Minimum

Minimum

Maximum

Maximum

2012 Term Loan

2012 Term Loan

2012 Term Loan

Amendment 1 2012 Term Loan

Amendment 1 2012 Term Loan

Amendment 2 2012 Term Loan

Amendment 2 2012 Term Loan

Amendment 2 2012 Term Loan

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver Amendment 3

Term Loans

Term Loans

Term B-2

Revolving Credit Facility

Term Loans

Revolving Credit Facility

Federal Funds Rate

Federal Funds Rate

LIBOR

LIBOR

LIBOR

LIBOR

Base Rate

LIBOR

Base Rate

Amendment 1 2012 Term Loan

Amendment 2 2012 Term Loan

Amendment 2 2012 Term Loan

2012 ABL Revolver

2012 Term Loan

2012 ABL Revolver

Term Loans

Revolving Credit Facility

Term Loans

Revolving Credit Facility

Term Loans

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

2012 Term Loan

2012 ABL Revolver

2012 Term Loan

2012 ABL Revolver

2012 Term Loan

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

2012 ABL Revolver

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

$660,000,000

'

'

'

'

$720,000,000

$720,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity term

'

'

'

'

'

'7 years

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, increase in borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85,000,000

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate, increase (decrease)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-0.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, discount, percentage

'

'

'

'

'

'

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of long-term debt

'

'

'

'

'

'

650,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs capitalized

'

'

'

'

20,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of subsidiary owned

'

'

100.00%

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, basis spread on variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

3.13%

3.50%

'

'

'

'

'

'

'

1.00%

'

'

'

'

Debt instrument, reference rate floor

'

'

'

'

'

'

'

'

'

1.00%

1.00%

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, quarterly payment, percent of original principal amount

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, step down interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.25%

'

'

'

'

'

'

'

'

'

'

'

'

Current portion of long term debt

$7,200,000

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, basis spread on variable rate, fixed component

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

0.50%

0.50%

1.00%

1.00%

'

'

'

'

'

Debt instrument, average interest rate during period

'

'

'

'

'

'

'

4.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

'

0.75%

'

'

'

'

'

'

'

'

'

Debt instrument, conditional variable rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

1.00%

2.25%

1.25%

Line of credit facility, commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, conditional commitment fee percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, interest rate at period end

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LongTerm_Debt_2013_Senior_Note

Long-Term Debt (2013 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]	'	'
Percentage of subsidiary owned	100.00%	100.00%
Senior Notes | 2013 Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	400,000,000	'
Debt instrument, stated interest rate	5.38%	'
Debt issuance costs capitalized	7,200,000	'

LongTerm_Debt_Redemptions_and_

Long-Term Debt (Redemptions and Restrictions) (Details) (USD $)

6 Months Ended

6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Senior Notes

Senior Notes

Term Loans

Prior to February 1, 2016

Prior to February 1, 2015

Upon Change in Control

Prior to December 15, 2016

On Or After December 15, 2016

Revolving Credit Facility

2012 Senior Notes

2013 Senior Notes

2012 Term Loan

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

2012 ABL Revolver

2012 Senior Notes

2012 Senior Notes

2012 Senior Notes

2013 Senior Notes

2013 Senior Notes

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, redemption price, percentage of principal amount

'

'

'

'

101.00%

'

100.00%

108.13%

101.00%

100.00%

105.38%

'

Debt instrument, percentage of principal amount eligible for redemption

'

'

'

'

'

'

'

35.00%

'

35.00%

'

'

Unamortized debt issuance costs

$32,900,000

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, unamortized discount

6,289,000

'

3,086,000

'

'

'

'

'

'

'

'

'

Unamortized debt issuance expense and discount

'

'

'

9,400,000

6,600,000

21,800,000

'

'

'

'

'

1,400,000

Repayments of long-term debt

$25,000,000

$7,500,000

'

'

'

'

'

'

'

'

'

$66,100,000

LongTerm_Debt_Schedule_of_Long

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt, gross	$1,698,600	$937,500
Current portion of long-term debt	7,200	0
Principal amount	1,691,400	937,500
Less: unamortized discount	-6,289	-3,086
Long-term debt, net of unamortized discount	1,685,111	934,414
2012 ABL Revolver | Revolving Credit Facility	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	66,100	0
Senior Notes | 2013 Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	400,000	400,000
Senior Notes | 2012 Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	250,000	250,000
Term Loans | 2012 Term Loan	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	262,500	287,500
Term Loans | Amendment 2 2012 Term Loan	'	'
Debt Instrument [Line Items]	'	'
Long-term debt, gross	$720,000	$0

LongTerm_Debt_Maturities_of_Lo

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2015 (remaining six months ending March 31, 2015)	$3,600	'
2016	7,200	'
2017	73,300	'
2018	7,200	'
2019	269,700	'
Thereafter	1,337,600	'
Long-term debt, gross	$1,698,600	$937,500

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)

Sep. 30, 2014

Dec. 17, 2013

Sep. 30, 2014

Mar. 31, 2014

Jan. 31, 2012

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 31, 2014

Jan. 31, 2012

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 03, 2014

Revolving Credit Facility

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Term Loans

Term Loans

Term Loans

Term Loans

Term Loans

Term B-2

Term B-2

2012 ABL Revolver

2013 Senior Notes

2013 Senior Notes

2013 Senior Notes

2012 Senior Notes

2012 Senior Notes

2012 Senior Notes

Nonrecurring

Nonrecurring

Nonrecurring

Nonrecurring

2012 Term Loan

2012 Term Loan

2012 Term Loan

Nonrecurring

Nonrecurring

Amendment 2 2012 Term Loan

Amendment 2 2012 Term Loan

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Fair Value, Inputs, Level 2

Fair Value, Inputs, Level 2

Fair Value, Inputs, Level 2

Fair Value, Inputs, Level 2

Carrying Value

Carrying Value

Fair Value, Inputs, Level 2

Fair Value, Inputs, Level 2

2013 Senior Notes

2013 Senior Notes

2012 Senior Notes

2012 Senior Notes

2012 Term Loan

2012 Term Loan

Market Value

Market Value

Market Value

Market Value

Market Value

Market Value

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loans payable, fair value disclosure

'

'

$400,000,000

$400,000,000

'

$250,000,000

$250,000,000

$377,000,000

$408,500,000

$266,900,000

$280,600,000

'

$262,500,000

$287,500,000

$261,200,000

$288,900,000

'

'

Debt instrument, face amount

'

400,000,000

'

'

250,000,000

'

'

'

'

'

'

660,000,000

'

'

'

'

720,000,000

720,000,000

Debt instrument, fair value disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

718,200,000

'

Line of credit, fair value disclosure

$66,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			Restricted Shares	Restricted Shares	Restricted Shares	Restricted Shares
Class of Stock [Line Items]	'	'	'	'	'	'
Common stock, shares authorized	250,000,000	250,000,000	'	'	'	'
Common stock, par value (in USD per share)	$0.01	$0.01	'	'	'	'
Preferred stock, shares authorized	5,000,000	5,000,000	'	'	'	'
Preferred stock, par value (in USD per share)	$0.01	$0.01	'	'	'	'
Voting rights, number of votes per common share owned	1	'	'	'	'	'
Restricted stock repurchased during period, shares	'	'	13,924	0	47,664	10,726
Restricted stock acquired, average cost per share	'	'	'	'	$33.63	$25.96

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income (Components of AOCI) (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income [Abstract]	'	'
Cumulative translation adjustment	($7,365)	$739
Total accumulated other comprehensive (loss) income, net of tax	($7,365)	$739

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator	'	'	'	'
Net income	$16,463	$32,792	$33,195	$53,484
Denominator	'	'	'	'
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	52,088	51,463	52,023	51,343
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)	506	756	541	787
Denominator for diluted earnings per share (in shares)	52,594	52,219	52,564	52,130
Earnings per Common Share:	'	'	'	'
Basic net earnings per share (in USD per share)	$0.32	$0.64	$0.64	$1.04
Diluted net earnings per share (in USD per share)	$0.31	$0.63	$0.63	$1.03

Earnings_Per_Share_Antidilutiv

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Outstanding Stock Awards	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, shares	0.3	0.2	0.3	0.2

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Aug. 28, 2014

Aug. 28, 2014

12-May-14

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

12-May-14

Sep. 30, 2014

12-May-14

12-May-14

2005 Long-Term Incentive Plan

2005 Long-Term Incentive Plan

Restricted Shares

Restricted Shares

Restricted Shares

Restricted Shares

Restricted Shares

Stock Options

Stock Options

Employee

Employee

Director

Group One

Group Two

Minimum

Maximum

Minimum

Maximum

Restricted Shares

Stock Options

Restricted Shares

Restricted Shares

Restricted Shares

Share-based Compensation, Aggregate Disclosures:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, number of additional shares authorized

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in USD per share)

$0.01

'

$0.01

'

$0.01

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation costs charged against income

$1.50

$1.30

$3.40

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit recognized from share-based compensation expense

0.5

0.3

1.2

0.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period

'

'

'

'

'

'

'

'3 years

'

'

'3 years

'5 years

'3 years

'5 years

'3 years

'3 years

'1 year

'

'

Granted in period (in shares)

'

'

'

'

'

'

'

96,638

'

'

'

'

'

'

'

'

'

75,638

21,000

Percentage of stock units vesting annually

'

'

'

'

'

'

'

33.30%

'

'

'

'

'

'

'

33.30%

'

'

'

Granted, weighted-average grant-date fair value (in USD per share)

'

'

'

'

'

'

'

'

$33.30

$30.19

'

'

'

'

'

'

'

'

'

Options, Additional Disclosures:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award exercisability period, from date of grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'10 years

'

'

'

Options granted in period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

307,490

'

'

'

Options granted, weighted-average grant-date fair value (in USD per share)

'

'

$15.93

$13.94

'

'

'

'

'

'

'

'

'

'

'

$33.50

'

'

'

Options exercised, aggregate intrinsic value

'

'

7.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to nonvested awards

7.4

'

7.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs related to nonvested awards, weighted average period for recognition

'

'

'1 year 0 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of vested shares

'

'

4.2

3.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash received from exercise of stock options

'

'

2.8

5.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit realized from exercise of stock options

'

'

$1.80

$1.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for issuance under the Plan

1,200,000

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Restri

Share-Based Compensation Restricted Stock Units Activity) (Details) (Restricted Stock Units (RSUs), USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock Units (RSUs)	'	'
Shares	'	'
Outstanding, beginning of period (in shares)	437,500	421,300
Granted (in shares)	104,400	120,600
Vested and issued (in shares)	120,700	-54,700
Forfeited (in shares)	-14,400	-3,600
Outstanding, end of period (in shares)	406,800	483,600
Vested, end of period (in shares)	76,600	83,100
Weighted- Average Grant-Date Fair Value	'	'
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$16.76	$11.01
Granted, weighted-average grant-date fair value (in USD per share)	$33.30	$30.19
Vested and issued, weighted-average grant-date fair value (in USD per share)	$13.34	$8.11
Forfeited, weighted-average grant-date fair value (in USD per share)	$20.78	$13.24
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$21.88	$16.11
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$11.62	$9.63

ShareBased_Compensation_Stock_

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected volatility	47.30%	48.00%
Expected dividends	$0	$0
Expected term in years	'6 years 0 months	'6 years 0 months
Risk-free rate	2.20%	1.30%

ShareBased_Compensation_Stock_1

Share-Based Compensation (Stock Option Activity) (Details) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Shares	'	'
Outstanding, beginning of period (in shares)	994,900	1,386,400
Granted (in shares)	307,500	227,700
Exercised (in shares)	-284,400	-539,400
Forfeited or expired (in shares)	-32,500	-8,000
Outstanding, end of period (in shares)	985,500	1,066,700
Exercisable, end of period (in shares)	416,000	225,500
Weighted- Average Exercise Price	'	'
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$15.24	$10.43
Granted, weighted-average exercise price (in USD per share)	$33.50	$29.94
Exercised, weighted-average exercise price (in USD per share)	$9.70	$9.54
Forfeited or expired, weighted-average exercise price (in USD per share)	$25.61	$13.24
Outstanding, end of period, weighted-average exercise price (in USD per share)	$22.19	$15.02
Exercisable, end of period, weighted-average exercise price (in USD per share)	$14.31	$11.42
Options, Additional Disclosures:	'	'
Outstanding, end of period, weighted-average remaining contractual term	'8 years	'6 years 6 months
Exercisable, end of period, weighted-average remaining contractual term	'6 years 9 months 18 days	'7 years 8 months 12 days
Outstanding, end of period, aggregate intrinsic value	$10,364	$16,110
Exercisable, end of period, aggregate intrinsic value	$7,514	$4,216

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'	'	'	'	'
Effective income tax rate	41.90%	12.10%	41.20%	24.50%	'
One-time benefit due to recent tax law change	'	'	$9.10	'	'
Net operating loss carryforwards	78.2	'	78.2	'	'
Operating loss carryforwards, limitation on use, annual amount	33.6	'	33.6	'	'
Uncertain tax liability	$1.20	'	$1.20	'	$1.20

Commitments_and_Contingencies_1

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			sqft
Operating Leased Assets [Line Items]	'	'	'	'
Additional space	'	'	15,470	'
2015 (Remaining six months ending March 31, 2015)	$1,203,000	'	$1,203,000	'
2016	1,923,000	'	1,923,000	'
2017	1,849,000	'	1,849,000	'
2018	1,856,000	'	1,856,000	'
2019	1,864,000	'	1,864,000	'
Thereafter	2,465,000	'	2,465,000	'
Total future minimum payments due	11,160,000	'	11,160,000	'
Rent expense	300,000	500,000	700,000	800,000
Facilities	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
2015 (Remaining six months ending March 31, 2015)	859,000	'	859,000	'
2016	1,612,000	'	1,612,000	'
2017	1,772,000	'	1,772,000	'
2018	1,856,000	'	1,856,000	'
2019	1,864,000	'	1,864,000	'
Thereafter	2,465,000	'	2,465,000	'
Total future minimum payments due	10,428,000	'	10,428,000	'
Equipment	'	'	'	'
Operating Leased Assets [Line Items]	'	'	'	'
2015 (Remaining six months ending March 31, 2015)	344,000	'	344,000	'
2016	311,000	'	311,000	'
2017	77,000	'	77,000	'
2018	0	'	0	'
2019	0	'	0	'
Thereafter	0	'	0	'
Total future minimum payments due	$732,000	'	$732,000	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Nov. 01, 2009	Sep. 30, 2014
Third-party Manufacturing	'	'
Long-term Purchase Commitment [Line Items]	'	'
Supply agreement, term	'10 years	'
2015 (Remaining six months ending March 31, 2015)	'	$549
2016	'	1,074
2017	'	1,044
2018	'	1,013
2019	'	982
Thereafter	'	560
Total purchase commitment	'	$5,222

Concentrations_of_Risk_Details

Concentrations of Risk (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			brand
Concentration Risk [Line Items]	'	'	'	'
Number of third-party manufacturers	101	50	101	50
Sales | Product Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	40.60%	41.80%	41.20%	43.00%
Number of highest selling brands comprising group against which concentration risk is measured	'	'	5	'
Sales | Customer Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	17.00%	19.20%	18.00%	20.40%
Number of customers exceeding concentration risk benchmark	'	'	1	1
Sales | Supplier Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	77.40%	77.90%
Number of third-party manufacturers with long-term contracts	'	'	47	22
Accounts Receivable | Customer Concentration Risk	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	'	21.50%	'

Business_Segments_Information_

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	$180,005	$165,507	$324,546	$307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of sales	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Advertising and promotion	25,044	24,547	44,140	43,228
Contribution margin	77,498	68,675	140,268	133,018
Other operating expenses	30,980	14,913	50,947	29,815
Operating income	46,518	53,762	89,321	103,203
Other expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Geographic Concentration Risk | Sales	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	'	10.00%	'	'
Geographic Concentration Risk | Sales | United States	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	82.70%	86.90%	83.50%	87.80%
Geographic Concentration Risk | Sales | Canada	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	7.40%	7.20%	6.60%	7.60%
Geographic Concentration Risk | Sales | Australia	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	'	8.10%	7.60%	'
Geographic Concentration Risk | Goodwill and Intangible Assets | United States	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	'	'	95.00%	'
Geographic Concentration Risk | Goodwill and Intangible Assets | Australia	'	'	'	'
Geographic Areas, Revenues from External Customers [Abstract]	'	'	'	'
Concentration risk, percentage	'	'	5.00%	'
North American OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	137,428	132,125	247,685	251,061
Other revenues	150	150	327	300
Total revenues	137,578	132,275	248,012	251,361
Cost of sales	52,185	50,987	94,526	94,533
Gross profit	85,393	81,288	153,486	156,828
Advertising and promotion	21,442	22,547	37,794	40,097
Contribution margin	63,951	58,741	115,692	116,731
International OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	17,331	9,008	31,022	12,422
Other revenues	23	7	58	14
Total revenues	17,354	9,015	31,080	12,436
Cost of sales	6,595	4,338	11,679	5,803
Gross profit	10,759	4,677	19,401	6,633
Advertising and promotion	3,035	1,446	5,375	1,710
Contribution margin	7,724	3,231	14,026	4,923
Household Cleaning	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	25,246	24,374	45,839	43,666
Other revenues	1,091	1,281	2,040	1,994
Total revenues	26,337	25,655	47,879	45,660
Cost of sales	19,947	18,398	36,358	32,875
Gross profit	6,390	7,257	11,521	12,785
Advertising and promotion	567	554	971	1,421
Contribution margin	5,823	6,703	10,550	11,364
Operating Segments	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	180,715	166,326	325,973	307,968
Operating Segments | North American OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	138,138	132,944	249,112	251,880
Operating Segments | International OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	17,331	9,008	31,022	12,422
Operating Segments | Household Cleaning	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	25,246	24,374	45,839	43,666
Intersegment Eliminations	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	-710	-819	-1,427	-819
Intersegment Eliminations | North American OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	-710	-819	-1,427	-819
Intersegment Eliminations | International OTC Healthcare	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	0	0	0	0
Intersegment Eliminations | Household Cleaning	'	'	'	'
Segment Reporting Information, Profit (Loss):	'	'	'	'
Net sales	$0	$0	$0	$0

Business_Segments_Revenue_by_P

Business Segments (Revenue by Product) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	$181,269	$166,945	$326,971	$309,457
Analgesics	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	29,864	30,041	55,560	58,206
Cough & Cold	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	30,231	33,718	55,073	55,199
Women's Health	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	9,777	1,134	10,663	1,621
Gastrointestinal	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	26,494	21,996	49,630	43,765
Eye & Ear Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	25,433	21,003	50,800	43,595
Dermatologicals	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	18,146	18,321	30,949	33,043
Oral Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	13,061	13,158	23,310	24,291
Other OTC	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	1,926	1,919	3,107	4,077
Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	26,337	25,655	47,879	45,660
North American OTC Healthcare	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	137,578	132,275	248,012	251,361
North American OTC Healthcare | Analgesics	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	29,072	29,343	54,103	57,479
North American OTC Healthcare | Cough & Cold	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	24,771	28,695	44,814	49,193
North American OTC Healthcare | Women's Health	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	9,119	501	9,487	988
North American OTC Healthcare | Gastrointestinal	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	20,896	21,695	41,534	43,453
North American OTC Healthcare | Eye & Ear Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	21,405	19,378	42,130	39,710
North American OTC Healthcare | Dermatologicals	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	17,459	17,716	29,720	32,347
North American OTC Healthcare | Oral Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	12,934	13,028	23,121	24,114
North American OTC Healthcare | Other OTC	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	1,922	1,919	3,103	4,077
North American OTC Healthcare | Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
International OTC Healthcare	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	17,354	9,015	31,080	12,436
International OTC Healthcare | Analgesics	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	792	698	1,457	727
International OTC Healthcare | Cough & Cold	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	5,460	5,023	10,259	6,006
International OTC Healthcare | Women's Health	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	658	633	1,176	633
International OTC Healthcare | Gastrointestinal	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	5,598	301	8,096	312
International OTC Healthcare | Eye & Ear Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	4,028	1,625	8,670	3,885
International OTC Healthcare | Dermatologicals	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	687	605	1,229	696
International OTC Healthcare | Oral Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	127	130	189	177
International OTC Healthcare | Other OTC	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	4	0	4	0
International OTC Healthcare | Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	26,337	25,655	47,879	45,660
Household Cleaning | Analgesics	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Cough & Cold	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Women's Health	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	'	0
Household Cleaning | Gastrointestinal	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Eye & Ear Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Dermatologicals	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Oral Care	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Other OTC	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	0	0	0	0
Household Cleaning | Household Cleaning	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	$26,337	$25,655	$47,879	$45,660

Business_Segments_Assets_by_Se

Business Segments (Assets by Segment) (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	$293,993	$190,911
Indefinite-lived intangibles	1,941,058	'
Finite-lived intangibles	222,889	'
Intangible assets, net (excluding goodwill)	2,163,947	1,394,817
Intangible assets, net (including goodwill)	2,457,940	'
North American OTC Healthcare	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	263,411	160,157
Indefinite-lived intangibles	1,723,498	'
Finite-lived intangibles	196,145	'
Intangible assets, net (excluding goodwill)	1,919,643	'
Intangible assets, net (including goodwill)	2,183,054	'
International OTC Healthcare	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	23,193	23,365
Indefinite-lived intangibles	97,740	'
Finite-lived intangibles	1,449	'
Intangible assets, net (excluding goodwill)	99,189	'
Intangible assets, net (including goodwill)	122,382	'
Household Cleaning	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Goodwill	7,389	7,389
Indefinite-lived intangibles	119,820	'
Finite-lived intangibles	25,295	'
Intangible assets, net (excluding goodwill)	145,115	'
Intangible assets, net (including goodwill)	$152,504	'

Condensed_Consolidating_Financ2

Condensed Consolidating Financial Statements Narrative (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Prestige Brands, Inc., the issuer or the borrower	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Corrections adjustment for equity in income of subsidiaries	($48.10)	$48.10
Corrections adjustment for cumulative adjustment	'	1
Prestige Brands Holdings, Inc.	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Corrections adjustment for equity in income of subsidiaries	0.6	0.6
Eliminations	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Corrections adjustment for equity in income of subsidiaries	47.5	47.5
Combined Subsidiary Guarantors	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Corrections adjustment for cumulative adjustment	'	$1

Condensed_Consolidating_Financ3

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	'	'	'	'
Net sales	$180,005	$165,507	$324,546	$307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Operating Expenses	'	'	'	'
Advertising and promotion	25,044	24,547	44,140	43,228
General and administrative	27,128	11,619	44,134	23,253
Depreciation and amortization	3,852	3,294	6,813	6,562
Total operating expenses	56,024	39,460	95,087	73,043
Operating income	46,518	53,762	89,321	103,203
Other (income) expense	'	'	'	'
Interest income	-15	-25	-47	-28
Interest expense	18,208	16,464	32,893	32,372
Equity in (income) loss of subsidiaries	0	0	0	0
Total other (income) expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	5,633	33,914	25,091	54,607
Prestige Brands Holdings, Inc.	'	'	'	'
Revenues	'	'	'	'
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses	'	'	'	'
Advertising and promotion	0	0	0	0
General and administrative	1,109	891	2,254	2,390
Depreciation and amortization	870	517	1,512	1,034
Total operating expenses	1,979	1,408	3,766	3,424
Operating income	-1,979	-1,408	-3,766	-3,424
Other (income) expense	'	'	'	'
Interest income	-12,245	-12,778	-24,378	-24,991
Interest expense	8,629	8,687	17,177	17,294
Equity in (income) loss of subsidiaries	-17,577	-30,344	-33,256	-50,199
Total other (income) expense	-21,193	-34,435	-40,457	-57,896
Income before income taxes	19,214	33,027	36,691	54,472
Provision for income taxes	2,751	235	3,496	988
Net income	16,463	32,792	33,195	53,484
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	5,633	33,914	25,091	54,607
Prestige Brands, Inc., the issuer or the borrower	'	'	'	'
Revenues	'	'	'	'
Net sales	27,167	25,237	52,577	49,386
Other revenues	95	67	225	135
Total revenues	27,262	25,304	52,802	49,521
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	10,426	9,338	19,874	18,796
Gross profit	16,836	15,966	32,928	30,725
Operating Expenses	'	'	'	'
Advertising and promotion	2,699	3,594	5,388	6,924
General and administrative	3,441	1,481	5,914	3,124
Depreciation and amortization	145	143	290	285
Total operating expenses	6,285	5,218	11,592	10,333
Operating income	10,551	10,748	21,336	20,392
Other (income) expense	'	'	'	'
Interest income	-16,719	-14,005	-30,944	-28,328
Interest expense	18,208	16,464	32,893	32,372
Equity in (income) loss of subsidiaries	-9,825	-20,599	-20,723	-35,152
Total other (income) expense	-8,336	-18,140	-18,774	-31,108
Income before income taxes	18,887	28,888	40,110	51,500
Provision for income taxes	3,262	1,064	6,979	4,151
Net income	15,625	27,824	33,131	47,349
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	4,795	28,946	25,027	48,472
Combined Subsidiary Guarantors	'	'	'	'
Revenues	'	'	'	'
Net sales	138,336	132,821	247,234	249,091
Other revenues	1,241	1,431	2,340	2,294
Total revenues	139,577	134,252	249,574	251,385
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	64,812	61,513	115,327	111,502
Gross profit	74,765	72,739	134,247	139,883
Operating Expenses	'	'	'	'
Advertising and promotion	19,311	19,556	33,377	34,700
General and administrative	20,329	8,358	29,319	16,815
Depreciation and amortization	2,729	2,589	4,818	5,184
Total operating expenses	42,369	30,503	67,514	56,699
Operating income	32,396	42,236	66,733	83,184
Other (income) expense	'	'	'	'
Interest income	-1,760	-710	-2,522	-710
Interest expense	20,333	18,093	38,138	36,021
Equity in (income) loss of subsidiaries	-1,870	-1,189	-911	-1,868
Total other (income) expense	16,703	16,194	34,705	33,443
Income before income taxes	15,693	26,042	32,028	49,741
Provision for income taxes	4,976	2,922	11,202	11,738
Net income	10,717	23,120	20,826	38,003
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	-113	24,242	12,722	39,126
Combined Non-Guarantor Subsidiaries	'	'	'	'
Revenues	'	'	'	'
Net sales	15,212	7,449	26,163	8,672
Other revenues	436	668	838	1,102
Total revenues	15,648	8,117	27,001	9,774
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	5,767	3,600	9,790	4,136
Gross profit	9,881	4,517	17,211	5,638
Operating Expenses	'	'	'	'
Advertising and promotion	3,034	1,397	5,375	1,604
General and administrative	2,249	889	6,647	924
Depreciation and amortization	108	45	193	59
Total operating expenses	5,391	2,331	12,215	2,587
Operating income	4,490	2,186	4,996	3,051
Other (income) expense	'	'	'	'
Interest income	-11	-22	-40	-24
Interest expense	1,758	710	2,522	710
Equity in (income) loss of subsidiaries	0	0	0	0
Total other (income) expense	1,747	688	2,482	686
Income before income taxes	2,743	1,498	2,514	2,365
Provision for income taxes	873	310	1,603	498
Net income	1,870	1,188	911	1,867
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	-10,830	1,122	-8,104	1,123
Total other comprehensive (loss) income	-10,830	1,122	-8,104	1,123
Comprehensive income	-8,960	2,310	-7,193	2,990
Eliminations	'	'	'	'
Revenues	'	'	'	'
Net sales	-710	0	-1,428	0
Other revenues	-508	-728	-978	-1,223
Total revenues	-1,218	-728	-2,406	-1,223
Cost of Sales	'	'	'	'
Cost of sales (exclusive of depreciation shown below)	-2,278	-728	-2,428	-1,223
Gross profit	1,060	0	22	0
Operating Expenses	'	'	'	'
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	1,060	0	22	0
Other (income) expense	'	'	'	'
Interest income	30,720	27,490	57,837	54,025
Interest expense	-30,720	-27,490	-57,837	-54,025
Equity in (income) loss of subsidiaries	29,272	52,132	54,890	87,219
Total other (income) expense	29,272	52,132	54,890	87,219
Income before income taxes	-28,212	-52,132	-54,868	-87,219
Provision for income taxes	0	0	0	0
Net income	-28,212	-52,132	-54,868	-87,219
Comprehensive income, net of tax:	'	'	'	'
Currency translation adjustments	32,490	-3,366	24,312	-3,369
Total other comprehensive (loss) income	32,490	-3,366	24,312	-3,369
Comprehensive income	$4,278	($55,498)	($30,556)	($90,588)

Condensed_Consolidating_Financ4

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]	'	'	'	'
Ownership percentage	100.00%	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	$21,748	$28,331	$26,833	$15,670
Accounts receivable, net	98,644	65,050	'	'
Inventories	82,875	65,586	'	'
Deferred income tax assets	9,171	6,544	'	'
Prepaid expenses and other current assets	9,935	11,674	'	'
Total current assets	222,373	177,185	'	'
Property and equipment, net	12,420	9,597	'	'
Goodwill	293,993	190,911	'	'
Intangible assets, net	2,163,947	1,394,817	'	'
Other long-term assets	32,937	23,153	'	'
Intercompany receivables	0	0	'	'
Investment in subsidiary	0	0	'	'
Total Assets	2,725,670	1,795,663	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	7,200	0	'	'
Accounts payable	58,538	48,286	'	'
Accrued interest payable	12,086	9,626	'	'
Other accrued liabilities	34,086	26,446	'	'
Total current liabilities	111,910	84,358	'	'
Long-term debt	'	'	'	'
Principal amount	1,691,400	937,500	'	'
Less unamortized discount	-6,289	-3,086	'	'
Long-term debt, net of unamortized discount	1,685,111	934,414	'	'
Deferred income tax liabilities	334,297	213,204	'	'
Other long-term liabilities	313	327	'	'
Intercompany payables	0	0	'	'
Total Liabilities	2,131,631	1,232,303	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	524	520	'	'
Additional paid-in capital	421,574	414,387	'	'
Treasury stock, at cost	-3,034	-1,431	'	'
Accumulated other comprehensive (loss) income, net of tax	-7,365	739	'	'
Retained earnings (accumulated deficit)	182,340	149,145	'	'
Total Stockholders' Equity	594,039	563,360	'	'
Total Liabilities and Stockholders' Equity	2,725,670	1,795,663	'	'
Prestige Brands Holdings, Inc.	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	10,465	24,644	23,667	14,720
Accounts receivable, net	7	473	'	'
Inventories	0	0	'	'
Deferred income tax assets	1,139	260	'	'
Prepaid expenses and other current assets	2,841	8,004	'	'
Total current assets	14,452	33,381	'	'
Property and equipment, net	8,580	8,966	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Other long-term assets	0	0	'	'
Intercompany receivables	1,203,499	655,146	'	'
Investment in subsidiary	1,519,129	1,497,357	'	'
Total Assets	2,745,660	2,194,850	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	0	'	'	'
Accounts payable	2,084	4,416	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	6,407	7,728	'	'
Total current liabilities	8,491	12,144	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	0	0	'	'
Other long-term liabilities	0	0	'	'
Intercompany payables	2,143,130	1,619,346	'	'
Total Liabilities	2,151,621	1,631,490	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	524	520	'	'
Additional paid-in capital	421,574	414,387	'	'
Treasury stock, at cost	-3,034	-1,431	'	'
Accumulated other comprehensive (loss) income, net of tax	-7,365	739	'	'
Retained earnings (accumulated deficit)	182,340	149,145	'	'
Total Stockholders' Equity	594,039	563,360	'	'
Total Liabilities and Stockholders' Equity	2,745,660	2,194,850	'	'
Prestige Brands, Inc., the issuer or the borrower	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,352	14,245	'	'
Inventories	9,666	14,357	'	'
Deferred income tax assets	823	925	'	'
Prepaid expenses and other current assets	354	113	'	'
Total current assets	25,195	29,640	'	'
Property and equipment, net	90	112	'	'
Goodwill	66,007	66,007	'	'
Intangible assets, net	192,593	192,861	'	'
Other long-term assets	32,937	23,153	'	'
Intercompany receivables	2,688,676	1,824,482	'	'
Investment in subsidiary	1,213,732	749,947	'	'
Total Assets	4,219,230	2,886,202	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	7,200	'	'	'
Accounts payable	9,508	7,658	'	'
Accrued interest payable	12,086	9,626	'	'
Other accrued liabilities	2,970	2,117	'	'
Total current liabilities	31,764	19,401	'	'
Long-term debt	'	'	'	'
Principal amount	1,691,400	937,500	'	'
Less unamortized discount	-6,289	-3,086	'	'
Long-term debt, net of unamortized discount	1,685,111	934,414	'	'
Deferred income tax liabilities	58,076	56,827	'	'
Other long-term liabilities	0	0	'	'
Intercompany payables	995,186	451,497	'	'
Total Liabilities	2,770,137	1,462,139	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	0	0	'	'
Additional paid-in capital	1,280,948	1,280,945	'	'
Treasury stock, at cost	0	0	'	'
Accumulated other comprehensive (loss) income, net of tax	-7,365	739	'	'
Retained earnings (accumulated deficit)	175,510	142,379	'	'
Total Stockholders' Equity	1,449,093	1,424,063	'	'
Total Liabilities and Stockholders' Equity	4,219,230	2,886,202	'	'
Combined Subsidiary Guarantors	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	5,034	0	0	0
Accounts receivable, net	76,165	45,885	'	'
Inventories	67,420	46,309	'	'
Deferred income tax assets	6,743	4,914	'	'
Prepaid expenses and other current assets	6,023	2,898	'	'
Total current assets	161,385	100,006	'	'
Property and equipment, net	2,297	226	'	'
Goodwill	204,794	101,540	'	'
Intangible assets, net	1,871,933	1,169,943	'	'
Other long-term assets	0	0	'	'
Intercompany receivables	599,886	656,759	'	'
Investment in subsidiary	79,877	34,562	'	'
Total Assets	2,920,172	2,063,036	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	0	'	'	'
Accounts payable	42,634	33,553	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	20,746	13,443	'	'
Total current liabilities	63,380	46,996	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	276,180	156,327	'	'
Other long-term liabilities	0	0	'	'
Intercompany payables	1,295,207	1,037,105	'	'
Total Liabilities	1,634,767	1,240,428	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	0	0	'	'
Additional paid-in capital	1,131,578	681,503	'	'
Treasury stock, at cost	0	0	'	'
Accumulated other comprehensive (loss) income, net of tax	-7,365	739	'	'
Retained earnings (accumulated deficit)	161,192	140,366	'	'
Total Stockholders' Equity	1,285,405	822,608	'	'
Total Liabilities and Stockholders' Equity	2,920,172	2,063,036	'	'
Combined Non-Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	6,249	3,687	3,166	950
Accounts receivable, net	8,120	4,447	'	'
Inventories	6,777	5,930	'	'
Deferred income tax assets	466	445	'	'
Prepaid expenses and other current assets	717	659	'	'
Total current assets	22,329	15,168	'	'
Property and equipment, net	1,453	293	'	'
Goodwill	23,192	23,364	'	'
Intangible assets, net	99,421	32,013	'	'
Other long-term assets	0	0	'	'
Intercompany receivables	10,045	13,595	'	'
Investment in subsidiary	0	0	'	'
Total Assets	156,440	84,433	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	0	'	'	'
Accounts payable	4,312	2,659	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	3,963	3,158	'	'
Total current liabilities	8,275	5,817	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	41	50	'	'
Other long-term liabilities	313	327	'	'
Intercompany payables	68,583	42,034	'	'
Total Liabilities	77,212	48,228	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	0	0	'	'
Additional paid-in capital	74,031	23,815	'	'
Treasury stock, at cost	0	0	'	'
Accumulated other comprehensive (loss) income, net of tax	-7,365	739	'	'
Retained earnings (accumulated deficit)	12,562	11,651	'	'
Total Stockholders' Equity	79,228	36,205	'	'
Total Liabilities and Stockholders' Equity	156,440	84,433	'	'
Eliminations	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	'	'
Inventories	-988	-1,010	'	'
Deferred income tax assets	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	-988	-1,010	'	'
Property and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Other long-term assets	0	0	'	'
Intercompany receivables	-4,502,106	-3,149,982	'	'
Investment in subsidiary	-2,812,738	-2,281,866	'	'
Total Assets	-7,315,832	-5,432,858	'	'
Current liabilities	'	'	'	'
Current portion of long term debt	0	'	'	'
Accounts payable	0	0	'	'
Accrued interest payable	0	0	'	'
Other accrued liabilities	0	0	'	'
Total current liabilities	0	0	'	'
Long-term debt	'	'	'	'
Principal amount	0	0	'	'
Less unamortized discount	0	0	'	'
Long-term debt, net of unamortized discount	0	0	'	'
Deferred income tax liabilities	0	0	'	'
Other long-term liabilities	0	0	'	'
Intercompany payables	-4,502,106	-3,149,982	'	'
Total Liabilities	-4,502,106	-3,149,982	'	'
Stockholders' Equity	'	'	'	'
Preferred share rights	0	'	'	'
Common stock	0	0	'	'
Additional paid-in capital	-2,486,557	-1,986,263	'	'
Treasury stock, at cost	0	0	'	'
Accumulated other comprehensive (loss) income, net of tax	22,095	-2,217	'	'
Retained earnings (accumulated deficit)	-349,264	-294,396	'	'
Total Stockholders' Equity	-2,813,726	-2,282,876	'	'
Total Liabilities and Stockholders' Equity	($7,315,832)	($5,432,858)	'	'

Condensed_Consolidating_Financ5

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating Activities	'	'
Net income (loss)	$33,195	$53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	6,815	6,562
Deferred income taxes	11,496	4,355
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs	3,403	2,487
Amortization of debt discount	687	798
Gain (loss) on sale of assets	56	-3
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-8,363	-5,712
Inventories	7,264	821
Prepaid expenses and other current assets	3,114	2,619
Accounts payable	-5,647	-1,125
Accrued liabilities	2,640	-10,663
Net cash provided by operating activities	57,058	55,598
Investing Activities	'	'
Purchases of property and equipment	-1,380	-2,319
Proceeds from sale of property and equipment	0	3
Proceeds from the sale of business	18,500	0
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666	0
Acquisition of Hydralyte	-77,991	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	-55,215
Intercompany activity, net	0	0
Net cash provided by (used in) investing activities	-810,537	-57,531
Financing Activities	'	'
Term loan borrowings	720,000	0
Term loan repayments	-25,000	-7,500
Repayments under revolving credit agreement	-58,500	-35,500
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	-16,072	-275
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	-1,660	-278
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	747,212	12,940
Effects of exchange rate changes on cash and cash equivalents	-316	156
(Decrease) Increase in cash and cash equivalents	-6,583	11,163
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,748	26,833
Prestige Brands Holdings, Inc.	'	'
Operating Activities	'	'
Net income (loss)	33,195	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	1,512	1,034
Deferred income taxes	-879	-14
Amortization of deferred financing costs	'	0
Stock-based compensation costs	3,403	2,487
Amortization of debt discount	'	0
Gain (loss) on sale of assets	'	0
Equity in income of subsidiaries	-33,256	-50,199
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	466	-112
Inventories	0	0
Prepaid expenses and other current assets	5,163	2,656
Accounts payable	-2,332	-517
Accrued liabilities	-1,321	-6,218
Net cash provided by operating activities	5,951	2,601
Investing Activities	'	'
Purchases of property and equipment	-1,127	-2,216
Proceeds from sale of property and equipment	'	0
Proceeds from the sale of business	0	'
Acquisition of Insight Pharmaceuticals, less cash acquired	0	'
Acquisition of Hydralyte	0	'
Acquisition of Care Pharmaceuticals, less cash acquired	'	0
Intercompany activity, net	'	0
Net cash provided by (used in) investing activities	-1,127	-2,216
Financing Activities	'	'
Term loan borrowings	'	'
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57	'
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	-1,660	-278
Intercompany activity, net	-21,187	2,347
Net cash provided by (used in) financing activities	-19,003	8,562
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	-14,179	8,947
Cash and cash equivalents - beginning of period	24,644	14,720
Cash and cash equivalents - end of period	10,465	23,667
Prestige Brands, Inc., the issuer or the borrower	'	'
Operating Activities	'	'
Net income (loss)	33,131	47,349
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	290	285
Deferred income taxes	1,351	-642
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs	'	0
Amortization of debt discount	687	798
Gain (loss) on sale of assets	'	0
Equity in income of subsidiaries	-20,723	-35,152
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-107	996
Inventories	4,691	-1,975
Prepaid expenses and other current assets	-241	-147
Accounts payable	1,850	-1,296
Accrued liabilities	3,313	177
Net cash provided by operating activities	26,640	12,368
Investing Activities	'	'
Purchases of property and equipment	'	0
Proceeds from sale of property and equipment	'	0
Proceeds from the sale of business	0	'
Acquisition of Insight Pharmaceuticals, less cash acquired	0	'
Acquisition of Hydralyte	0	'
Acquisition of Care Pharmaceuticals, less cash acquired	'	0
Intercompany activity, net	-809,157	-55,215
Net cash provided by (used in) investing activities	-809,157	-55,215
Financing Activities	'	'
Term loan borrowings	720,000	'
Term loan repayments	-25,000	-7,500
Repayments under revolving credit agreement	-58,500	-35,500
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	-16,072	-275
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	'
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	37,489	36,122
Net cash provided by (used in) financing activities	782,517	42,847
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors	'	'
Operating Activities	'	'
Net income (loss)	20,826	38,003
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	4,818	5,184
Deferred income taxes	11,084	5,011
Amortization of deferred financing costs	'	0
Stock-based compensation costs	'	0
Amortization of debt discount	'	0
Gain (loss) on sale of assets	0	-3
Equity in income of subsidiaries	-911	-1,868
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-4,496	-5,323
Inventories	1,857	3,073
Prepaid expenses and other current assets	-1,718	-787
Accounts payable	-6,997	-1,473
Accrued liabilities	-701	-3,011
Net cash provided by operating activities	23,762	38,806
Investing Activities	'	'
Purchases of property and equipment	-87	0
Proceeds from sale of property and equipment	'	3
Proceeds from the sale of business	18,500	'
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666	'
Acquisition of Hydralyte	0	'
Acquisition of Care Pharmaceuticals, less cash acquired	'	0
Intercompany activity, net	731,166	0
Net cash provided by (used in) investing activities	-87	3
Financing Activities	'	'
Term loan borrowings	'	'
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	'
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	-18,641	-38,809
Net cash provided by (used in) financing activities	-18,641	-38,809
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	5,034	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	5,034	0
Combined Non-Guarantor Subsidiaries	'	'
Operating Activities	'	'
Net income (loss)	911	1,867
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	195	59
Deferred income taxes	-60	0
Amortization of deferred financing costs	'	0
Stock-based compensation costs	'	0
Amortization of debt discount	'	0
Gain (loss) on sale of assets	56	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	-4,226	-1,273
Inventories	738	-277
Prepaid expenses and other current assets	-90	493
Accounts payable	1,832	2,161
Accrued liabilities	1,349	-1,207
Net cash provided by operating activities	705	1,823
Investing Activities	'	'
Purchases of property and equipment	-166	-103
Proceeds from sale of property and equipment	'	0
Proceeds from the sale of business	0	'
Acquisition of Insight Pharmaceuticals, less cash acquired	'	'
Acquisition of Hydralyte	-77,991	'
Acquisition of Care Pharmaceuticals, less cash acquired	'	-55,215
Intercompany activity, net	77,991	55,215
Net cash provided by (used in) investing activities	-166	-103
Financing Activities	'	'
Term loan borrowings	'	'
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	'
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	2,339	340
Net cash provided by (used in) financing activities	2,339	340
Effects of exchange rate changes on cash and cash equivalents	-316	156
(Decrease) Increase in cash and cash equivalents	2,562	2,216
Cash and cash equivalents - beginning of period	3,687	950
Cash and cash equivalents - end of period	6,249	3,166
Eliminations	'	'
Operating Activities	'	'
Net income (loss)	-54,868	-87,219
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	0	0
Deferred income taxes	0	0
Amortization of deferred financing costs	'	0
Stock-based compensation costs	'	0
Amortization of debt discount	'	0
Gain (loss) on sale of assets	'	0
Equity in income of subsidiaries	54,890	87,219
Changes in operating assets and liabilities, net of effects from acquisitions	'	'
Accounts receivable	0	0
Inventories	-22	0
Prepaid expenses and other current assets	0	404
Accounts payable	0	0
Accrued liabilities	0	-404
Net cash provided by operating activities	0	0
Investing Activities	'	'
Purchases of property and equipment	'	0
Proceeds from sale of property and equipment	'	0
Proceeds from the sale of business	0	'
Acquisition of Insight Pharmaceuticals, less cash acquired	0	'
Acquisition of Hydralyte	0	'
Acquisition of Care Pharmaceuticals, less cash acquired	'	0
Intercompany activity, net	'	0
Net cash provided by (used in) investing activities	0	0
Financing Activities	'	'
Term loan borrowings	'	'
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0	'
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$0	$0